



1
A03

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/00, A01K 67/027, C07K 16/00 A2
 (11) International Publication Number: WO 98/24893
 (43) International Publication Date: 11 June 1998 (11.06.98)

(21) International Application Number: PCT/US97/23091
 (22) International Filing Date: 3 December 1997 (03.12.97)
 (30) Priority Data: 08/759,620 3 December 1996 (03.12.96) US
 (71) Applicant: ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US).
 (72) Inventors: JAKOBIVITS, Aya; 2021 Monterey Avenue, Menlo Park, CA 94025 (US). KUCHERLAPATI, Raju; 8 Gracie Lane, Darien, CT 06820 (US). KLAPHOLZ, Sue; 76 Peter Coutts Circle, Stanford, CA 94305 (US). MENDEZ, Michael; P.O. Box 787, El Granada, CA 94018 (US). GREEN, Larry; 70 Crestline Drive #2, San Francisco, CA 94131 (US).
 (74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING PLURAL VH AND V κ REGIONS AND ANTIBODIES PRODUCED THEREFROM

(57) Abstract

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V μ and V κ) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development in the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Ga ^o on	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mongolia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Malta	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Mauritius	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Dem. People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING PLURAL
V_H AND V_K REGIONS AND ANTIBODIES PRODUCED THEREFROM

10

FIELD OF THE INVENTION

15

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V_{H} and V_{κ}) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

BACKGROUND OF THE TECHNOLOGY

13

The ability to clone and reconstruct megabase-sized human loci in YACs and to introduce them into the mouse germline provides a powerful approach to elucidating the functional components of very large or crudely mapped loci as well as generating useful models of human disease. Furthermore, the utilization of such technology for substitution of mouse loci with their human equivalents could provide unique insights into the expression and regulation of human gene products during development, their communication with other systems, and their involvement in disease induction and progression.

An important practical application of such a strategy is the "humanization" of the mouse humoral immune system. Introduction of human immunoglobulin (Ig) loci into mice in which the endogenous Ig genes have been inactivated offers the opportunity to study of the mechanisms underlying programmed expression and assembly of antibodies as well as their role in B-cell development. Furthermore, such a strategy could provide an ideal source for production of fully human monoclonal antibodies (Mabs) - an important milestone towards fulfilling the promise of antibody therapy in human disease. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the administered antibodies. The use of fully human antibodies can be expected to provide a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which require repeated antibody administrations.

One approach towards this goal was to engineer mouse strains deficient in mouse antibody production with large fragments of the human Ig loci in anticipation that such mice would produce a large repertoire of human antibodies in the absence of mouse antibodies. Large human Ig fragments would preserve the large variable gene diversity as well as the proper regulation of antibody production and expression. By exploiting the mouse machinery for antibody diversification and selection and the lack of immunological tolerance to human proteins, the reproduced human antibody repertoire in these mouse strains should yield high affinity antibodies against any antigen of interest, including human antigens. Using the hybridoma technology, antigen-specific human Mabs with the desired specificity could be readily produced and selected.

This general strategy was demonstrated in connection with our generation of the first XenoMouse™ strains as published in 1994. See Green et al. *Nature Genetics* 7:13-21 (1994). The XenoMouse™ strains were engineered with 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain loci and kappa light chain loci, respectively, which contained core variable and constant region sequences. *Id.* The human Ig containing yeast artificial chromosomes (YACs) proved to be compatible with the mouse system for both rearrangement and expression of antibodies, and were capable of substituting for the inactivated mouse Ig genes. This was demonstrated by their ability to induce B-cell development and to produce an adult-like human

repertoire of fully human antibodies and to generate antigen-specific human Mabs. These results also suggested that introduction of larger portions of the human Ig loci containing greater numbers of V genes, additional regulatory elements, and human Ig constant regions might recapitulate substantially the full repertoire that is characteristic of the human humoral response to infection and immunization.

Such approach is further discussed and delineated in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 07/922,649, filed July 30, 1992, filed 08/031,801, filed March 15, 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/376,279, filed January 20, 1995, 08/430,938, April 27, 1995, 08/464,584, filed June 5, 1995, 08/464,582, filed June 5, 1995, 08/463,191, filed June 5, 1995, 08/462,837, filed June 5, 1995, 08/486,853, filed June 5, 1995, 08/486,857, filed June 5, 1995, 08/486,859, filed June 5, 1995, 08/462,513, filed June 5, 1995, and 08/724,752, filed October 2, 1996. *See also* European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, and PCT Application No. PCT/US96/05928, filed April 29, 1996. The disclosures of each of the above-cited patents and applications are hereby incorporated by reference in their entirety.

In an alternative approach, others, including GenPharm International, Inc., have utilized a "minilocus" approach. In the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more V_H genes, one or more D_H genes, one or more J_H genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal. This approach is described in U.S. Patent No. 5,545,807 to Surani et al. and U.S. Patent Nos. 5,545,806 and 5,625,825, both to Lonberg and Kay, and GenPharm International U.S. Patent Application Serial Nos. 07/574,748, filed August 29, 1990, 07/575,962, filed August 31, 1990, 07/810,279, filed December 17, 1991, 07/853,408, filed March 18, 1992, 07/904,063, filed June 23, 1992, 07/990,860, filed December 16, 1992, 08/053,131, filed April 26, 1993, 08/096,762, filed July 22, 1993, 08/155,301, filed November 18, 1993, 08/161,739, filed December 3, 1993, 08/165,699, filed December 10, 1993, 08/209,741, filed March 9, 1994, the disclosures of which are hereby incorporated by reference. *See also* International Patent Application Nos. WO 94/25585, published

November 10, 1994, WO 93 12227, published June 24, 1993, WO 92 22645, published December 23, 1992, WO 92 03918, published March 19, 1992, the disclosures of which are hereby incorporated by reference in their entirety. *See further* Taylor et al., 1992, Chen et al., 1993, Tuauion et al., 1993, Choi et al., 1993, Lonberg et al., 1994, Taylor et al., 1994, and Tuauion et al., 1995, the disclosures of which are hereby incorporated by reference in their entirety.

The inventors of Surani et al., cited above, and assigned to the Medical Research Council (the "MRC"), produced a transgenic mouse possessing an Ig locus through use of the minilocus approach. The inventors on the GenPharm International work, cited above, Lonberg and Kay, following the lead of the present inventors, proposed inactivation of the endogenous mouse Ig locus coupled with substantial duplication of the Surani et al. work.

An advantage of the minilocus approach is the rapidity with which constructs including portions of the Ig locus can be generated and introduced into animals. Commensurately, however, a significant disadvantage of the minilocus approach is that, in theory, insufficient diversity is introduced through the inclusion of small numbers of V, D, and J genes. Indeed, the published work appears to support this concern. B-cell development and antibody production of animals produced through use of the minilocus approach appear stunted. Therefore, the present inventors have consistently urged introduction of large portions of the Ig locus in order to achieve greater diversity and in an effort to reconstitute the immune repertoire of the animals.

Accordingly, it would be desirable to provide transgenic animals containing more complete germline sequences and configuration of the human Ig locus. It would be additionally desirable to provide such locus against a knockout background of endogenous Ig

SUMMARY OF THE INVENTION

Provided in accordance with the present invention are transgenic animals having a near complete human Ig locus, including both a human heavy chain locus and a human kappa light chain locus. Preferably, the heavy chain locus includes greater than about 20%, more preferably greater than about 40%, more preferably greater than about 50%, and even more preferably greater than about 60% of the human heavy chain variable region. In connection with the human kappa light chain, preferably, the locus includes greater than about 20%, more preferably greater than about 40%.

more preferably greater than about 50%, and even more preferably greater than about 50% of the human kappa light chain variable region. Such percentages preferably refer to percentages of functional variable region genes.

Further, preferably such animals include the entire D_{μ} region, the entire J_{μ} region, the human mu constant region, and can additionally be equipped with genes encoding other human constant regions for the generation of additional isotypes. Such isotypes can include genes encoding γ_1 , γ_2 , γ_3 , α , ϵ , β , and other constant region encoding genes. Alternative constant regions can be included on the same transgene, i.e., downstream from the human mu constant region, or, alternatively, such other constant regions can be included on another chromosome. It will be appreciated that where such other constant regions are included on the same chromosome as the chromosome including the human mu constant region encoding transgene, cis-switching to the other isotype or isotypes can be accomplished. On the other hand, where such other constant region is included on a different chromosome from the chromosome containing the mu constant region encoding transgene, trans-switching to the other isotype or isotypes can be accomplished. Such arrangement allows tremendous flexibility in the design and construction of mice for the generation of antibodies to a wide array of antigens.

Preferably, such mice additionally do not produce functional endogenous immunoglobulins. This is accomplished in a preferred embodiment through the inactivation (or knocking out) of endogenous heavy and light chain loci. For example, in a preferred embodiment, the mouse heavy chain J-region and mouse kappa light chain J-region and C_{κ} -region are inactivated through utilization of homologous recombination vectors that replace or delete the region. Such techniques are described in detail in our earlier applications and publications.

Unexpectedly, transgenic mice in accordance with the invention appear to possess an almost entirely reconstituted immune system repertoire. This is dramatically demonstrated when four separate mouse strains are compared: a first strain contains extensive human heavy chain variable regions and human kappa light chain variable regions and encodes only a mu isotype, a second strain contains extensive human heavy chain variable regions and human kappa light chain variable regions and encodes a mu and gamma-2 isotypes, a third strain contains significantly less human heavy and kappa light chain variable regions, and a fourth strain contains a double-inactivated mouse Ig locus.

The first and second strains undergo similar, if not identical, B-cell development, whereas the third strain has a reduced development and maturation of B-cells, and the fourth strain contains no mature B-cells. Further, it is interesting to note that production of human antibodies in preference to murine antibodies is substantially elevated in mice having a knock-out background of endogenous Ig. That is to say that mice that contain a human Ig locus and a functionally inactivated endogenous Ig produce human antibodies at a rate of approximately 100 to 1000 fold as efficiently as mice that contain only a human Ig locus.

Thus, in accordance with a first aspect of the present invention there is provided a transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising an inactivated endogenous immunoglobulin (Ig) locus, such that the mammal would not display normal B-cell development; an inserted human heavy chain Ig locus in substantially germline configuration, the human heavy chain Ig locus comprising a human mu constant region and regulatory and switch sequences thereto, a plurality of human J_{H} genes, a plurality of human D_{H} genes, and a plurality of human V_{H} genes; and an inserted human kappa light chain Ig locus in substantially germline configuration, the human kappa light chain Ig locus comprising a human kappa constant region, a plurality of J_{K} genes, and a plurality of V_{K} genes, wherein the number of V_{H} and V_{K} genes inserted are selected to substantially restore normal B-cell development in the mammal. In a preferred embodiment, the heavy chain Ig locus comprises a second constant region selected from the group consisting of human gamma-1, human gamma-2, human gamma-3, human gamma-4, alpha, delta, and epsilon. In another preferred embodiment, the number of V_{H} genes is greater than about 20. In another preferred embodiment, the number of V_{K} genes is greater than about 15. In another preferred embodiment, the number of D_{H} genes is greater than about 25, the number of J_{H} genes is greater than about 4, the number of V_{H} genes is greater than about 20, the number of J_{K} genes is greater than about 4, and the number of V_{K} genes is greater than about 15. In another preferred embodiment, the number of D_{H} genes, the number of J_{H} genes, the number of V_{H} genes, the number of J_{K} genes, and the number of V_{K} genes are selected such that the Ig loci are capable of encoding greater than about 1×10^5 different functional antibody sequence combinations. In a preferred embodiment, in a population of mammals B-cell function is reconstituted on average to greater than about 50% as compared to wild type.

In accordance with a second aspect of the present invention there is provided an improved transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous immunoglobulin molecules, the improvement comprising: insertion into the genome of the mammal of sufficient human V_H , D_H , J_H , V_K , and J_K genes such that the mammal is capable of encoding greater than about 1×10^6 different functional human immunoglobulin sequence combinations.

In accordance with a third aspect of the present invention, there is provided an improved transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous immunoglobulin molecules, the modifications, with respect to the mammal's incapacity to produce functional endogenous immunoglobulin molecules would not allow the mammal to display normal B-cell development, the improvement comprising: insertion into the genome of the mammal of sufficient human V_H , D_H , J_H , V_K , and J_K genes such that the mammal is capable of encoding greater than about 1×10^6 different functional human immunoglobulin sequence combinations and sufficient V_H and V_K genes to substantially restore normal B-cell development in the mammal. In a preferred embodiment, in a population of mammals B-cell function is reconstituted on average to greater than about 50% as compared to wild type.

In accordance with a fourth aspect of the present invention, there is provided a transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising: an inactivated endogenous heavy chain immunoglobulin (Ig) locus; an inactivated endogenous kappa light chain Ig locus; an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of $\gamma H2$; and an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of $\gamma K2$.

In accordance with a fifth aspect of the present invention there is provided a transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising: an inactivated endogenous heavy chain immunoglobulin (Ig) locus; an inserted human

heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2, and an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2

5 In accordance with a sixth aspect of the present invention, there is provided a transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising an inactivated endogenous heavy chain immunoglobulin (Ig) locus, an inactivated endogenous kappa light chain Ig locus, an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region, and an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2

10

15

20

In accordance with a seventh aspect of the present invention, there is provided a transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising an inactivated endogenous heavy chain immunoglobulin (Ig) locus, an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region, and an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2

25 In accordance with an eighth aspect of the present invention, there is provided a method for the production of human antibodies, comprising inoculating any of the mammals of the first through fifth aspects of the invention discussed above with an antigen, collecting and immortalizing lymphocytic cells to obtain an immortal cell population secreting human antibodies that specifically bind to the antigen with an affinity of greater than 10^9 M⁻¹, and isolating the antibodies from the immortal cell populations

In a preferred embodiment, the antigen is IL-8. In another preferred embodiment, the antigen is EGFR. In another preferred embodiment, the antigen is TNF- α

In accordance with a ninth aspect of the present invention, there is provided an antibody

produced by the method of the sixth aspect of the invention, including antibodies to IL-8, EGFR, and TNF- α .

In accordance with a tenth aspect of the present invention, there is provided an improved method for the production of transgenic mice, the transgenic mice having a genome, the genome comprising modifications, the modifications comprising insertion of a plurality of human variable regions, the improvement comprising: insertion of the human variable regions from a yeast artificial chromosome.

In accordance with an eleventh aspect of the present invention, there are provided transgenic mice and transgenic offspring therefrom produced through use of the improvement of the eighth aspect of the present invention.

In accordance with a twelfth aspect of the present invention, there is provided a transgenic mammal, the transgenic mammal comprising a genome, the genome comprising modifications, the modifications comprising an inserted human heavy chain immunoglobulin transgene, the improvement comprising: the transgene comprising selected sets of human variable region genes that enable human-like junctional diversity and human-like complementarity determining region 3 (CDR3) lengths. In a preferred embodiment, the human-like junctional diversity comprises average N-addition lengths of 7.7 bases. In another preferred embodiment, the human-like CDR3 lengths comprise between about 2 through about 25 residues with an average of about 14 residues.

20

BRIEF DESCRIPTION OF THE DRAWING FIGURES

Figure 1 is a schematic representation of the reconstructed human heavy chain and human kappa light chain loci YACs introduced into preferred mice in accordance with the invention. YACs spanning the human heavy chain (1H, 2H, 3H, and 4H) and the human kappa light chain proximal (1K, 2K, and 3K) loci were cloned from human -YAC libraries. The locations of the different YACs with respect to the human Ig loci (adopted from Cook and Tomlinson, 1995, and Cox et al., 1994), their sizes, and non-Ig sequences are indicated (not shown to scale). The YACs were recombined into yeast in a two-step procedure (see Materials and Methods) to reconstruct the human heavy and kappa light chain YACs. yH2, the human heavy chain containing YAC, was further retrofitted with a human γ_2 gene sequence. yK2, was the human kappa light chain containing YAC. The YAC vector

elements (telomere ▲, centromere ●, mammalian HPRT, Neo) and yeast selectable markers (TRP1, ADE2, LYS2, LEU2, T⁺RAS, HIS3) on the YAC vector arms are indicated. V_H segments are classified as genes with open reading frame ●, pseudogenes □, and unsequenced genes △. V_L segments are classified as genes with open reading frames ● and pseudogenes □. The V genes that we have found to be utilized by the XenoMouse II are marked (*). The V_H gene region contained on yH2 is marked by arrows.

Figure 2 is a series of Southern Blot analyses and characterizations of the human heavy chain YAC, yH2, integrated in ES cells and in XenoMouse strains. Figure 2a is a series of Southern Blot analyses of EcoRI (a, c) and BamHI (b, d, e) digested DNA (2 μ g) prepared from the CGM1 immortalized B-lymphoblast cell line derived from the Washington University YAC library source (Brownstein et al., 1989), yH2 YAC (0.5 μ g YAC added to 2 μ g of 3B1 DNA), unmodified E14TG 3B1 (3B1), and yH2-containing ES cell lines L10, J9 2, L18, L17, and J17. The probes used for blotting were human V_H1 (a), D_H (b) [18 kb fragment in CGM1 lane represents D segments on chromosome 16], V_H3 (c), C_H (d) and J_H (e). Figure 2b is a series of Southern Blot analyses of EcoRI (a-b) and BamHI (c-d) digested DNA (10 μ g) that was prepared from the tails of wildtype (WT, 129xB57BL/6J), XM2A-1, and XM2A-2 (2 individual offspring) mice or from the parental yH2-containing ES cell lines L10 (slightly underloaded relative to other samples), J9 2, and yK2-containing ES cell line J23 1. The probes used were human V_H1 (a), V_H4 (b), human γ -2 (c), and mouse 5'-enhancer (d, the 5kb band represents the endogenous mouse 5'-enhancer fragment).
20 Fragment sizes of molecular weight markers (in kb) are indicated.

Figure 3 is a series of Southern Blot analyses characterizing the human kappa light chain YAC, yK2, integrated in ES cells and in XenoMouse 2A Strains. Figure 2a is a series of Southern Blot analyses of EcoRI (a, c, d) and BamHI (b, e) digested DNA (2 μ g) prepared from CGM1 cell line (Brownstein et al., 1989 *supra*), yK2 YAC (0.5 μ g YAC DNA added to 2 μ g of 3B1 DNA), unmodified E14TG 3B1 (3B1), and yK2-containing ES cell lines J23 1 and J23 7. The probes used were human V_a (a), K_{de} (b), V_LII (c), V_LIII (d), and C_g (e). Figure 2b is a series of Southern Blot analyses of EcoRI-digested DNA (2 μ g) that was prepared from the tails of wildtype (WT, 129xB6), XM2A-1, and XM2A-2 (2 individual offspring) mice or from the parental yH2-containing ES cell lines L10 (slightly underloaded relative to other samples), J9 2, and yK2-containing ES cell line J23 1.

The probes that were used were human V₁I (a), V₂IV (b), V₃VI (c) and 3'-enhancer (d). Fragment sizes of molecular weight markers (in kb) are indicated

Figure 4 shows B-cell reconstitution and surface expression of human μ , δ , and κ chains on XenoMouse-derived B-cells and shows flow cytometry analysis of peripheral blood (Fig. 4a) and spleen (Fig. 4b) lymphocytes from wildtype mice (WT), double inactivated mice (DI), and XenoMouse strains 2A-1 and 2A-2 (XM2A-1, XM2A-2). Four-color flow cytometry analysis was carried out using antibodies to the B-cell-specific marker B220 in combination with anti-human μ , δ , κ , or mouse μ , δ , κ , or λ . The percentage of positively-stained cells is shown in each quadrant. Isolation and staining of cells were performed as described in Materials and Methods. Populations of human κ^+ and mouse λ^+ cells were determined after first gating for B220 $^+$ μ^+ populations in the indicated region. Populations of μ^+ and δ^+ cells were determined after first gating for B220 $^+$ cells. The percentage of positive cells within a region or quadrant is indicated. The FACS profiles shown are representative of several experiments performed on each of the strains

Figure 5 shows that XenoMouse-derived human antibodies block the binding of their specific antigens to cells. Figure 5a shows the inhibition of labeled [I^{125}]IL-8 binding to human neutrophils by the mouse anti-human IL-8 antibody (R&D Systems) (□) and the fully human Mabs D1.1 (◆), K2.2 (●), K4.2 (▲), and K4.3 (▼). The background binding of labeled [I^{125}]IL-8 in the absence of antibody was 2657 cpm. Figure 5b shows the inhibition of labeled [I^{125}]EGF to its receptors on A431 cells by mouse anti-human EGFR antibodies 225 and 528 (□, ▽, respectively, Calbiochem) and the fully human antibodies E1.1 (●), E2.4 (▲), E2.5 (▼) and E2.11 (◆). The background binding of [I^{125}]EGF in the absence of antibodies was 1060 cpm. Figure 5c shows inhibition of labeled [I^{125}]TNF- α binding to its receptors on U937 cells by the mouse anti-human TNF- α antibody (R&D Systems) (□) and fully human Mabs T22.1 (◆), T22.4 (●), T22.8 (▲), and T22.9 (■). The background binding of [I^{125}]TNF- α in the absence of antibody was 4010 cpm. Control human IgG₂ myeloma antibody (⊗).

Figure 6 shows repertoire and somatic hypermutation in XenoMouse-derived fully human Mabs. Predicted amino acid sequences of four anti-IL-8 (Fig. 6a) and four anti-EGFR (Fig. 6b) human IgG₁ Mabs, divided into CDR1, CDR2 and CDR3 and the constant regions, C₁2 and C₁3. The D and J genes of each antibody are indicated. The amino acid substitutions from the germline

sequences are indicated in bold letters

Figure 7 is a schematic diagram of the human heavy chain genome and the human kappa light chain genome

Figure 8 is another schematic diagram showing the construction of the γ H2 (human heavy chain) YAC

Figure 9 is another schematic diagram showing the construction of the γ K2 (human kappa light chain) YAC

Figure 10 is another schematic diagram showing the construction of the γ K2 (human kappa light chain) YAC

Figure 11 shows a series of Southern Blot analyses demonstrating integration intact of the γ H2 (human heavy chain) YAC into ES cells and into the mouse genome. Detailed discussion is provided in connection with Figure 2

Figure 12 shows a series of Southern Blot analyses demonstrating integration intact of the γ K2 (human kappa light chain) YAC into ES cells and into the mouse genome. Detailed discussion is provided in connection with Figure 3

Figure 13 shows B-cell reconstitution and surface expression of human α , δ , and κ chains and mouse λ chains on XenoMouse-derived B-cells and shows flow cytometry analysis of peripheral blood. Further details are provided in connection with Figure 4

Figure 14 shows production levels of human antibodies by XenoMouse II strains in comparison to murine antibody production by wild type mice

Figure 15 is a repertoire analysis of human heavy chain transcripts expressed in XenoMouse II strains

Figure 16 is a repertoire analysis of human kappa light chain transcripts expressed in XenoMouse II strains

Figure 17 is another depiction of the diverse utilization of human V_{H1} and V_{K1} genes that have been observed as utilized in XenoMouse II strains

Figure 18 shows the titers of human antibody production in XenoMouse II strains

Figure 19 is a depiction of gene utilization of anti-IL-8 antibodies derived from XenoMouse II strains

Figure 20 shows heavy chain amino acid sequences of anti-IL-8 antibodies derived from XenoMouse II strains

Figure 21 shows kappa light chain amino acid sequences of anti-IL-8 antibodies derived from XenoMouse II strains

5 **Figure 22** shows blockage of IL-8 binding to human neutrophils by human anti-IL-8 antibodies derived from XenoMouse II strains

Figure 23 shows inhibition of CD11b expression on human neutrophils by human anti-IL-8 antibodies derived from XenoMouse II strains

10 **Figure 24** shows inhibition of IL-8 induced calcium influx by human anti-IL-8 antibodies derived from XenoMouse II strains

Figure 25 shows inhibition of IL-8 RB/293 chemotaxis by human anti-IL-8 antibodies derived from XenoMouse II strains.

Figure 26 is a schematic diagram of a rabbit model of human IL-8 induced skin inflammation.

15 **Figure 27** shows the inhibition of human IL-8 induced skin inflammation in the rabbit model of Figure 26 with human anti-IL-8 antibodies derived from XenoMouse II strains

Figure 28 shows inhibition of angiogenesis of endothelial cells on a rat corneal pocket model by human anti-IL-8 antibodies derived from XenoMouse II strains.

Figure 29 is a depiction of gene utilization of human anti-EGFR antibodies derived from XenoMouse II strains.

20 **Figure 30** shows heavy chain amino acid sequences of human anti-EGFR antibodies derived from XenoMouse II strains

Figure 31 shows blockage EGF binding to A431 cells by human anti-EGFR antibodies derived from XenoMouse II strains.

25 **Figure 32** shows inhibition of EGF binding to SW948 cells by human anti-EGFR antibodies derived from XenoMouse II strains

Figure 33 shows that human anti-EGFR antibodies derived from XenoMouse II strains inhibit growth of SW948 cells *in vitro*.

Figure 34 shows inhibition of TNF- α binding to U937 cells through use of human anti-TNF- α antibodies derived from XenoMouse II strains.

Figure 35 shows kappa light chain amino acid sequences of human anti-EGFR antibodies derived from XenoMouse II strains

5

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Herein we describe the generation and characterization of several strains of mice containing substantially germline configuration megabase-sized human Ig loci. The present invention thus provides the first demonstration of reconstruction of the large and complex human Ig loci on YACs and the successful introduction of megabase-sized YACs into mice to functionally replace the 10 corresponding mouse loci

Mouse Strains

The following mouse strains are described and or utilized herein:

15 Double Inactivated (DI) Strain: The DI strain of mice are mice that do not produce functional endogenous, mouse, Ig. In preferred embodiments, the DI mice possess an inactivated mouse J_H region and an inactivated mouse C_K region. The construction of this strain is discussed extensively elsewhere. For example, the techniques utilized for generation of the DI strains are described in detail in U.S. Patent Application Serial Nos. 07/466,008, filed January 12, 1990, 07/610,515, filed November 8, 1990, 07/919,297, filed July 24, 1992, 08/031,801, filed March 15, 20 1993, 08/112,848, filed August 27, 1993, 08/234,145, filed April 28, 1994, 08/724,752, filed October 2, 1996. See also European Patent No., EP 0 463 151 B1, grant published June 12, 1996, International Patent Application No., WO 94/02602, published February 3, 1994, International Patent Application No., WO 96/34096, published October 31, 1996, and PCT Application No. 25 PCT/US96/05928, filed April 29, 1996. The disclosures of each of the above-cited patent and patent applications are hereby incorporated by reference in their entirety. It has been observed and reported that DI mice possess a very immature B-cell development. The mice do not produce mature B-cells, only pro-B-cells

XenoMouse I Strain: The design, construction, and analysis of the XenoMouse I strain was discussed in detail in Green et al., *Nature Genetics*, 7:13-21 (1994). Such mice produced IgM κ antibodies against a DI background. The mice showed improved B-cell function when compared to the DI strain of mice which have little to no B-cell development. While XenoMouse I strains of mice were capable of mounting a sizeable immune response to antigenic challenge, there appeared to be inefficient in their production of B-cells and possessed a limited response to different antigens which apparently was related to their limited V-gene repertoire.

L6 Strain: The L6 strain is a mouse producing IgM κ antibodies against a DI background of endogenous mouse Ig. L6 mice contain an inserted human heavy chain and an inserted human kappa light chain. The L6 strain is generated through breeding of a mouse containing a heavy chain insert against a double inactivated background (L6H) and a mouse having a kappa light chain insert against a double inactivated background (L6L). The heavy chain insert comprises an intact approximately 970 kb human DNA insert from a YAC containing approximately 66 V $_H$ segments, starting at V $_{H-1}$ and ending at V $_{H-65}$, and including the major D gene clusters (approximately 32), J $_H$ genes (6), the intronic enhancer (Em), Cu, and through about 25 kb past C δ , in germline configuration. The light chain insert comprises an intact approximately 800 kb human DNA insert from a YAC which contains approximately 32 V $_{\kappa}$ genes starting at V $_{\kappa-1}$ and ending at V $_{\kappa-61}$. The 800 kb insert contains a deletion of approximately 100 kb starting at V $_{\kappa-LP-13}$ and ending at V $_{\kappa-LP-5}$. However, the DNA is in germline configuration from V $_{\kappa-LP-13}$ to 100 kb past V $_{\kappa-Op-1}$, and also contains the J $_{\kappa}$ genes, the intronic and 3' enhancers, the constant C $_{\kappa}$ gene, and Kde. The L6H and L6L mice have been shown to access the full spectrum of the variable genes incorporated into their genome. It is expected that the L6 mice will similarly access the full spectrum of variable genes in their genome. Furthermore, L6 mice will exhibit predominant expression of human kappa light chain, a large population of mature B-cells, and normal levels of IgM $_{\kappa}$ human antibodies. Such mice will mount a vigorous human antibody response to multiple immunogens, ultimately yielding antigen-specific fully human Mabs with subnanomolar affinities.

XenoMouse IIa Strain: The XenoMouse IIa mice represent our second generation

XenoMouse™ strains equipped with germline configuration megabase-sized human Ig loci, against a DI background, such that the mice do not produce functional endogenous Ig. Essentially, the mice are equivalent in construction to the L6 strain, but additionally include the human $\gamma 2$ gene with its entire switch and regulatory sequences and the mouse 3' enhancer in *cis*. The mice contain an approximately 1020 kb heavy and an approximately 800 kb kappa light chain loci, reconstructed on YACs, which include the majority of the human variable region genes, including heavy chain genes (approximately 66 V_{H}) and kappa light chain genes (approximately 32 V_{L}), human heavy constant region genes (μ , δ , and γ) and kappa constant region genes (C_{L}), and all of the major identified regulatory elements. These mice have been shown to access the full spectrum of the variable genes incorporated into their genome. Furthermore, they exhibit efficient class switching and somatic hypermutation, predominant expression of human kappa light chain, a large population of mature B-cells, and normal levels of IgM_h and IgG_h human antibodies. Such mice mount a vigorous human antibody response to multiple immunogens, including human IL-8, human EGF receptor (EGFR), and human tumor necrosis factor- α (TNF- α), ultimately yielding antigen-specific fully human Mabs with subnanomolar affinities. This last result conclusively demonstrates XenoMouse™ as an excellent source for rapid isolation of high affinity, fully human therapeutic Mabs against a broad spectrum of antigens with any desired specificity.

As will be appreciated from the above-introduction, the XenoMouse II strain appears to undergo mature B-cell development and mount powerful adult-human-like immune responses to antigenic challenge. The L6 strain, as predicted from the data in connection with L6L and L6H mice, also appear to undergo mature B-cell development and mount powerful adult-human-like immune responses to antigenic challenge. When DI mice are compared to XenoMouse I strains and DI and XenoMouse I strains are compared to L6 and XenoMouse II strains, a markedly different B-cell development profile is observed. Owing to this difference, it appears that the quantity and/or quality of variable region sequences introduced into the animals are essential to the induction B-cell maturation and development and the generation of an adult-human-like immune response. Thus, in addition to the strains' clear use in the generation of human antibodies, the strains provide a valuable tool for studying the nature of human antibodies in the normal immune response, as well as the abnormal response characteristic of autoimmune disease and other disorders.

Variable Region - Quantitative Diversity

It is predicted that the specificity of antibodies (i.e., the ability to generate antibodies to a wide spectrum of antigens and indeed to a wide spectrum of independent epitopes thereon) is dependent upon the variable region genes on the heavy chain (V_H) and kappa light chain (V_{κ}) genome. The 5 human heavy chain genome includes approximately 95 functional genes which encode variable regions of the human heavy chain of immunoglobulin molecules. In addition, the human light chain genome includes approximately 40 genes on its proximal end which encode variable regions of the human kappa light chain of immunoglobulin molecules. We have demonstrated that the specificity of antibodies can be enhanced through the inclusion of a plurality of genes encoding variable light and 10 heavy chains.

Provided in accordance with the present invention are transgenic mice having a substantial portion of the human Ig locus, preferably including both a human heavy chain locus and a human kappa light chain locus. In preferred embodiments, therefore, greater than 10% of the human V_H and V_{κ} genes are utilized. More preferably, greater than about 20%, 30%, 40%, 50%, 60%, or even 70% 15 or greater of V_H and V_{κ} genes are utilized. In a preferred embodiment, constructs including 32 genes on the proximal region of the V_{κ} light chain genome are utilized and 66 genes on the V_H portion of the genome are utilized. As will be appreciated, genes may be included either sequentially, i.e., in the order found in the human genome, or out of sequence, i.e., in an order other than that found in the human genome, or a combination thereof. Thus, by way of example, an entirely sequential portion 20 of either the V_H or V_{κ} genome can be utilized, or various V genes in either the V_H or V_{κ} genome can be skipped while maintaining an overall sequential arrangement, or V genes within either the V_H or V_{κ} genome can be reordered, and the like. In a preferred embodiment, the entire inserted locus is 25 provided in substantially germline configuration as found in humans. In any case, it is expected and the results described herein demonstrate that the inclusion of a diverse array of genes from the V_H and V_{κ} genome leads to enhanced antibody specificity and ultimately to enhanced antibody affinities.

Further, preferably such mice include the entire D_H region, the entire J_H region, the human mu constant region, and can additionally be equipped with other human constant regions for the coding and generation of additional isotypes of antibodies. Such isotypes can include genes encoding γ_1 , γ_2 , γ_3 , γ_4 , α , ϵ , and δ and other constant region encoding genes with appropriate switch and regulatory

sequences. As will be appreciated, and as discussed in more detail below, a variety of switch and regulatory sequences can be appropriately utilized in connection with any particular constant region selection.

The following Table indicates the diversity of antibody combinations that are possible in humans, based strictly on random V-D-J joining and combination with kappa light chains, without consideration of N-addition or somatic mutation events. Based on these considerations, there are greater than 3.8 million possible antibody combinations in humans, of any particular isotype.

TABLE I

10

Region	Heavy Chain	Kappa Light Chain
Variable "V"	~95	40
Diversity "D"	~32	--
Joining "J"	6	5
Combinations (VxDxJ)	18,240	200
Total Combinations (HC Combinations x LC Combinations)		3.65×10^6

20 In connection with a preferred embodiment of the invention, through the inclusion of about 66 V_H genes and 32 V_L genes in a mouse with a full complement of D_H , J_H , and J_L genes, the possible diversity of antibody production is on the order of 2.03×10^6 different antibodies. As before, such calculation does not take into account N-addition or somatic mutation events. Therefore, it will be appreciated that mice in accordance with the invention, such as the L6 and the
25 XenoMouse II strains, offer substantial antibody diversity. In preferred embodiments, mice are designed to have the capability of producing greater than 1×10^6 different heavy chain V-D-J combinations and kappa light chain V-J combinations, without accounting for N-additions or somatic mutation events.

Variable Region - Qualitative Diversity

In addition to quantitative diversity, quantitative selection of V-genes (i.e., large and diverse numbers of V-genes) and/or qualitative selection of V-genes (i.e., selection of particular V-genes) 5 appears to play a role in what we refer to herein as "qualitative diversity." Qualitative diversity, as used herein, refers to diversity in V-D-J rearrangements wherein junctional diversity and/or somatic mutation events are introduced. During heavy chain rearrangement, certain enzymes (RAG-1, RAG-2, and possibly others) are responsible for the cutting of the DNA representing the coding regions of 10 the antibody genes. Terminal deoxynucleotidyl transferase (Tdt) activity is upregulated which is responsible for N-terminal additions of nucleotides between the V-D and D-Jgene segments. Similar enzymes and others (SCID and other DNA repair enzymes) are responsible for the deletion that occurs at the junctions of these coding segments. With respect to junctional diversity, both N-addition events and formation of the complementarity determining region 3 (CDR3, are included 15 within such term. As will be appreciated, CDR3 is located across the D region and includes the V-D and D-J junctional events. Thus, N-additions and deletions during both D-J rearrangement and V-D rearrangement are responsible for CDR3 diversity

It has been demonstrated that there are certain differences between murine and human junctional diversities. In particular, some researchers have reported that murine N-addition lengths and CDR3 lengths are generally shorter than typical human N-addition lengths and CDR3 lengths. 20 Such groups have reported that, in humans, N-additions of about 7.7 bases in length, on average, are typically observed. Yamada et al. (1991) Mouse-like N-additions are more often on the order of about 3 bases in length, on average. Feeney et al. (1990) Similarly, human-like CDR3 lengths are longer than mouse-like CDR3's. In man CDR3 lengths of between 2 and 25 residues, with an average of 14 residues, is common. In mice, some groups have reported shorter average CDR3 lengths.

25 The junctional diversity created by N-additions and CDR3 additions play a clear role developing antibody specificity.

In accordance with the invention, rearranged V-D-J gene sequences show N-addition lengths that are comparable to expected adult-human N-addition lengths. Further, amino acid sequences across the open reading frame (ORF) corresponding to CDR3 sequences show CDR3 lengths that

are comparable to expected adult-human CDR3 lengths. Such data is indicative that quantitative variable region diversity, and/or qualitative variable region diversity results in human-like functional diversity. Such functional diversity is expected to lead to a more human-like antibody specificity.

5 Variable Region - Affinities

While we have not conclusively demonstrated a direct causal connection between the increased variable region inclusion and antibody specificity, it appears, and it is expected that through providing such diversity, the ability of the mouse to mount an immune response to a wide array of antigens is possible and enhanced. Additionally, such mice appear more equipped to mount immune 10 responses to a wide array of epitopes upon individual antigens or immunogens. From our data it also appears that antibodies produced in accordance with the present invention possess enhanced affinities. Such data includes comparisons between mice in accordance with the invention and the XenoMouse I strains, as well as consideration of the published results of GenPharm International and the MRC. In connection with the XenoMouse I strains, as mentioned above, such mice possessed inefficient B-cell production and a limited response to different antigens. Such result appeared related in part to 15 the limited V-gene repertoire. Similarly, results reported by GenPharm International and the MRC indicate a limited response to diverse antigens.

Without wishing to bound to any particular theory or mode of operation of the invention, it would appear that enhanced affinities appear to result from the provision of the large number of V regions. From our data, the provision of greater numbers and/or selection of qualities of V-gene sequences, enhances junctional diversity (N-additions and formation of complementarity determining region 3 ("CDR3") diversity), which is typical of an adult-human-like immune response, and which play a substantial role in affinity maturation of antibodies. It may also be that such antibodies are more effective and efficient in somatic mutation events that lead to enhanced affinities. Each of 20 junctional diversity and somatic mutation event, are discussed in additional detail below.

With respect to affinities, antibody affinity rates and constants derived through utilization of plural V_{H} and V_{L} genes (i.e., the use of 32 genes on the proximal region of the V_{L} light chain genome and 66 genes on the V_{H} portion of the genome) results in association rates (k_a in $M^{-1}S^{-1}$) of greater than about 0.50×10^6 , preferably greater than 2.00×10^6 , and more preferably greater than about 25

4.00 X 10⁻⁶, dissociation rates (kd in S⁻¹) of greater than about 1.00 X 10⁻⁴, preferably greater than about 2.00 X 10⁻⁴, and more preferably greater than about 4.00 X 10⁻⁴, and dissociation constant (in M) of greater than about 1.00 X 10⁻¹⁰, preferably greater than about 2.00 X 10⁻¹⁰, and more preferably greater than about 4.00 X 10⁻¹⁰.

5 Preferably, such mice additionally do not produce functional endogenous immunoglobulins. This is accomplished in a preferred embodiment through the inactivation (or knocking out) of endogenous heavy and light chain loci. For example, in a preferred embodiment, the mouse heavy chain J-region and mouse kappa light chain J-region and C_μ-region are inactivated through utilization of homologous recombination vectors that replace or delete the region.

10

Variable Region - B-cell Development

15 B-cell development is reviewed in Klaus *B Lymphocytes* (IRL Press (1990)) and Chapters 1-3 of *Immunoglobulin Genes* (Academic Press Ltd. (1989)), the disclosures of which are hereby incorporated by reference. Generally, in mammals, blood cell development, including B- and T-cell lymphocytes, originate from a common pluripotent stem cell. The lymphocytes, then, evolve from a common lymphoid progenitor cell. Following an early gestational period, B-cell initiation shifts from the liver to the bone marrow where it remains throughout the life of the mammal.

20 In the life cycle of a B-cell, the first generally recognizable cell is a pro-pre-B-cell which is found in the bone marrow. Such a cell has begun heavy chain V-D-J rearrangement, but does not yet make protein. The cell then evolves into a large, rapidly dividing, pre-B-cell I which is a cytoplasmically μ⁺ cell. This pre-B-cell I then stops dividing, shrinks, and undergoes light chain V-J rearrangement becoming a pre-B-cell II which expresses surface IgM, which leave the marrow as immature B-cells. Most of the emerging immature B-cells continue to develop and to produce surface IgD, indicative of their completion of differentiation and development as fully mature 25 immunocompetent peripheral B-cells, which reside primarily in the spleen. However, it is possible to eliminate the delta constant region and still obtain immunocompetent cells.

B-cell differentiation and development can be monitored and/or tracked through the use of surface markers. For example, the B220 antigen is expressed in relative abundance on mature B-cells in comparison to pre-B-cells I or II. Thus, cells that are B220⁺ and surface IgM⁺ (μ⁺) can be utilized

to determine the presence of mature B-cells. Additionally, cells can be screened for surface IgD expression (δ^+). Another antigen, heat stable antigen, is expressed by pre-B-cells II as they transition to the periphery (i.e., as they become μ^+ and/or $\mu^+ \delta^+$).

5

TABLE II

Marker	Bone Marrow			Spleen	
	pro-pre-B-cell	pre-B-cell I	pre-B-cell II emerging B-cell	immature B-cell	mature B-cell
B220	-	-	±	+	-
HSA	-	-	+	±	-
μ	-	-	+	+	-
δ^+	-	-	-	-	+

15 Assuming the presence of a functional copy of the $C\delta$ gene on the transgene

Through use of B-cell markers, such as those mentioned above, development and differentiation of B-cells can be monitored and assessed

20 We have previously demonstrated that DI mice (mice that do not undergo heavy chain V-D-J rearrangement or light chain V-J rearrangement) do not produce mature B-cells. In fact, such mice arrest at the production of pro-pre-B-cells and B-cells never move from the bone marrow to peripheral tissues, including the spleen. Thus, both B-cell development and antibody production are completely arrested. The same result is seen in mice that are only heavy chain inactivated. B-cell development and differentiation arrests in the bone marrow.

25 Our XenoMouse I strain produced functional, somewhat mature B-cells. However, the numbers of B-cells, in both the bone marrow and peripheral tissues, were significantly reduced relative to wild type mice.

30 In contrast, our XenoMouse II strains and L5 strains, unexpectedly possess almost complete B-cell reconstitution. Therefore, in accordance with the invention, we have demonstrated that

through the quantitative inclusion or qualitative inclusion of variable region genes B-cell differentiation and development can be greatly reconstituted. Reconstitution of B-cell differentiation and development is indicative of immune system reconstitution. In general, B-cell reconstitution is compared to wild type controls. Thus, in preferred embodiments of the invention, populations of 5 mice having inserted human variable regions possess greater than about 50% B-cell function when compared to populations of wild type mice.

Further, it is interesting to note that production of human antibodies in preference to mouse antibodies is substantially elevated in mice having a knock-out background of endogenous Ig. That is to say that mice that contain a human Ig locus and a functionally inactivated endogenous heavy 10 chain Ig locus produce human antibodies at a rate of approximately 100 to 1000 fold as efficiently as mice that only contain a human Ig locus and are not inactivated for the endogenous locus

Isotype Switching

As is discussed in detail herein, as expected, XenoMouse II mice undergo efficient and 15 effective isotype switching from the human transgene encoded mu isotype to the transgene encoded gamma-2 isotype. We have also developed XenoMouse II strains that contain and encode the human gamma-4 constant region. As mentioned above, mice in accordance with the invention can additionally be equipped with other human constant regions for the generation of additional isotypes. Such isotypes can include genes encoding γ_1 , γ_2 , γ_3 , γ_4 , α , ϵ , δ , and other constant region encoding 20 genes. Alternative constant regions can be included on the same transgene, i.e., downstream from the human mu constant region, or, alternatively, such other constant regions can be included on another chromosome. It will be appreciated that where such other constant regions are included on the same chromosome as the chromosome including the human mu constant region encoding transgene, cis-switching to the other isotype or isotypes can be accomplished. On the other hand, 25 where such other constant region is included on a different chromosome from the chromosome containing the mu constant region encoding transgene, trans-switching to the other isotype or isotypes can be accomplished. Such arrangement allows tremendous flexibility in the design and construction of mice for the generation of antibodies to a wide array of antigens.

It will be appreciated that constant regions have known switch and regulatory sequences that

they are associated with. All of the murine and human constant region genes had been sequenced and published by 1984. See Honjo et al. "Constant Region Genes of the Immunoglobulin Heavy Chain and the Molecular Mechanism of Class Switching" in *Immunoglobulin Genes* (Honjo et al. eds., Academic Press (1984)), the disclosure of which is hereby incorporated by reference. For example, in U.S. Patent Application Serial No. 07/574,748, the disclosure of which is hereby incorporated by reference, the cloning of the human gamma-1 constant region was prophesized based on known sequence information from the prior art. It was set forth that in the unarranged, unswitched gene, the entire switch region was included in a sequence beginning less than 5 kb from the 5' end of the first γ -1 constant exon. Therefore the switch region was also included in the 5' 5.3 kb HindIII fragment that was disclosed in Ellison et al. *Nucleic Acids Res.* 10:4071-4079 (1982). Similarly, Takahashi et al. *Cell* 29:671-679 (1982) also reported that the fragment disclosed in Ellison contained the switch sequence, and this fragment together with the 7.7 kb HindIII to BamHI fragment must include all of the sequences necessary for the heavy chain isotype switching transgene construction.

Thus, it will be appreciated that any human constant region of choice can be readily incorporated into mice in accordance with the invention without undue experimentation. Such constant regions can be associated with their native switch sequences (i.e., a human $\gamma_1, 2, 3, \text{ or } 4$ constant region with a human $\gamma_1, 2, 3, \text{ or } 4$ switch, respectively) or can be associated with other switch sequences (i.e., a human γ_1 constant region with a human γ_2 switch). Various 3' enhancer sequences can also be utilized, such as mouse, human, or rat, to name a few. Similarly other regulatory sequences can also be included.

As an alternative to, and/or in addition to, isotype switching *in vivo*, B-cells can be screened for secretion of "chimeric" antibodies. For example, the L6 mice, in addition to producing fully human IgM antibodies, produce antibodies having fully human heavy chain V, D, J regions coupled to mouse constant regions, such as a variety of gammmas (i.e., mouse IgG1, 2, 3, 4) and the like. Such antibodies are highly useful in their own right. For example, human constant regions can be included on the antibodies through *in vitro* isotype switching techniques well known in the art. Alternatively, and/or in addition, fragments (i.e., F(ab) and F(ab')₂ fragments) of such antibodies can be prepared which contain little or no mouse constant regions.

As discussed above, the most critical factor to antibody production is specificity to a desired antigen or epitope on an antigen. Class of the antibody, thereafter, becomes important according to the therapeutic need. In other words, will the therapeutic index of an antibody be enhanced by providing a particular isotype or class? Consideration of that question raises issues of complement fixation and the like, which then drives the selection of the particular class or isotype of antibody. Gamma constant regions assist in affinity maturation of antibodies. However, the inclusion of a human gamma constant region on a transgene is not required to achieve such maturation. Rather, the process appears to proceed as well in connection with mouse gamma constant regions which are trans-switched onto the mu encoded transgene.

10

MATERIALS AND METHODS

The following Materials and Methods were utilized in connection with the generation and characterization of mice in accordance with the present invention. Such Materials and Methods are meant to be illustrative and are not limiting to the present invention.

15

Cloning Human Ig-derived YACs: The Washington University (Brownstein et al., 1989) and the CEPH (Albertsen et al., 1990) human-YAC libraries were screened for YACs containing sequences from the human heavy and kappa light chain loci as previously described (Mendez et al. 1995). Cloning and characterization of 1H and 1K YACs was described by Mendez et al., (1995). 20 3H and 4H YACs were identified from the Washington University library using a V_H3 probe (0.55 kb PstI/NcoI, Berman et al, 1988). The 17H YAC was cloned from the GM1416 YAC library and determined to contain 130 kb of heavy chain variable sequences and a 150 kb chimeric region at its 3' end Matsuda et. al., 1993. 2K and 3K YACs were recovered from the CHEF library using V_H-specific primer (Albertsen et al., 1990).

25

YAC targeting and recombination: Standard methods for yeast growth, mating, sporulation, and phenotype testing were employed (Sherman et al, 1986). Targeting of YAC's and YAC vector arms with yeast and mammalian selectable markers to facilitate the screening of YAC recombinants in yeast or YAC integration into cells, was achieved by lithium acetate transformation (Scheistl and

Geutz (1984). After every targeting or recombination step the modified YAC(s) was analyzed by pulsed field gel electrophoresis and standard Southern Blots to determine the integrity of all sequences.

YAC targeting vectors were used for the interconversion of centric and acentric arms to reorient 17H and to retrofit its 5' arm with LEU2 and URA3 genes and its 3' arm with the HIS3 gene

5. See Fig. 1a and Mendez et al. 1993. The 4H centric arm was retrofitted with the yeast ADE2 gene and the human HPRT selectable markers. For the first recombination step, a diploid yeast strain was created and selected in which all three YACs 17H, 3H, and 4H were present, intact, and stably maintained. A three-way homologous recombination between the YAC overlapping regions was induced by sporulation and the desired recombinant was found by the selection of the outer yeast 10. selectable markers (ADE2 and HIS3) and negative selection (loss) of the internal marker URA3. The successful recombination created a 880 kb YAC containing 80% of the IgH variable region, starting at V_{H2-5} and extending 20 kb 5' of the V_{H3-65} gene. For the recombination of the 880 kb YAC to 1H, 1H was retrofitted with pICL, which adds the LYS2 gene to the centric arm (Hermanson et al. 1991). Using standard yeast mating, a diploid strain was selected containing both 1H and the 880 15. kb YAC. Upon sporulation and by use of overlapping homology, YAC-yeast recombination was carried out. With positive selection for the outer yeast markers (ADE2 and URA3) and screening for the loss of the internal markers (TRP1, LYS2, HIS3), an intact 970 kb YAC consisting of approximately 56 V_{H} segments, starting at V_{H6-1} and ending at V_{H3-65} was found. The YAC also contained the major D gene clusters, J_{H} genes, the intronic enhancer (E_I), C_H, up to 25 kb past C_D, 20. in germline configuration. This 970 kb YAC was then retrofitted with a targeting vector including a 23 kb EcoRI genomic fragment of the human γ -2 gene, including its switch and regulatory elements, a 7 kb XbaI fragment of the murine heavy chain 3' enhancer, neomycin gene driven by the metallothionein promoter (MMTNeo), and the yeast LYS2 gene. This vector, while bringing in these sequences on the 3' YAC arm, disrupts the URA3 gene.

25. As a first step toward creating yK2 YAC, by standard yeast mating a diploid yeast strain was selected in which retrofitted 1K and 3K YACs were both present, intact, and stably maintained. Using the same process as described in connection with the IgH construction, YAC-yeast recombination was carried out. Through use of positive selection for the outer yeast markers (LYS2, TRP1) and the screening for the loss of internal markers (URA3, TRP1), an intact 800 kb

recombinant product was found which contained 32 V_{κ} starting at $V_{\kappa-L3}$ and ending at $V_{\kappa-Lp1}$. The 300 kb YAC contains a deletion of approximately 100 kb starting at $V_{\kappa-Lp13}$ and ending at $V_{\kappa-Lp5}$. However, the YAC is in germline configuration from $V_{\kappa-Lp13}$ to 100 kb past $V_{\kappa-Lp1}$. The YAC also contains J_{κ} , the intronic and 3' enhancers, the constant C_{κ} , and Kde

5

YAC introduction into ES cells and mice: YAC-containing yeast spheroplasts were fused with E14 TG3B1 ES cells as described (Jakobovits et al., 1993a; Green et al., 1994). HAT-resistant colonies were expanded for analysis. YAC integrity was evaluated by Southern Blot analysis using protocols and probes described in Berman et al., (1988) and Mendez et al., (1994) and hybridization 10 conditions as described in Gemmil et al., (1991). Chimeric mice were generated by microinjection of ES cells into C57BL/6 blastocysts. YAC-containing offspring were identified by PCR analysis of tail DNA as described (Green et al., 1994). YAC integrity was evaluated by Southern Blot analysis using probes and conditions previously described, except that the blot probed with human $V_{\kappa}3$ was washed at 50°C.

15

Flow cytometry analysis: Peripheral blood and spleen lymphocytes obtained from 8-10 week old XenoMice and control mice were purified on Lympholyte M (Accurate) and treated with purified anti-mouse CD32/CD16 Fc receptor (Pharmingen, 01241D) to block non-specific binding to Fc receptors, stained with antibodies and analyzed on a FACStar^{PLUS} (Becton Dickinson, CELLQuest software). Antibodies used: allophycocyanin (APC) anti-B220 (Pharmingen, 01129A); biotin anti-human IgM (Pharmingen, 08072D), biotin anti-mouse IgM (Pharmingen, 02202D), fluorescein isothiocyanate (FITC) goat F(ab')₂ anti-human IgD (Southern Biotechnology, 2032-02); FITC anti-mouse IgD^a (Pharmingen, 05064D), FITC anti-mIgD^b (Pharmingen, 05074D); FITC anti-mouse λ (Pharmingen, 02174D), PE anti-human κ (Pharmingen, 08175A), PE anti-mouse κ (Pharmingen, 02155A). RED613TM-streptavidin (GibcoBRL, 19541-010) was used to detect biotinylated 20 25 antibodies.

Immunization and hybridoma generation: XenoMice (8 to 10 weeks old) were immunized intraperitoneally with 25 μ g of recombinant human IL-8 or with 5 μ g TNF- α (Biosource

International) emulsified in complete Freund's adjuvant for the primary immunization and in incomplete Freund's adjuvant for the additional immunizations carried out at two week intervals. For EGFR immunization, XenoMice were immunized intraperitoneally with 2x10⁷ A431 (ATCC CRL-7907) cells resuspended in phosphate buffered saline (PBS). This dose was repeated three times. Four days before fusion, the mice received a final injection of antigen or cells in PBS. Spleen and lymph node lymphocytes from immunized mice were fused with the non-secretory myeloma NSO-bcl2 line (Ray and Diamond, 1994), and were subjected to HAT selection as previously described (Galfre and Milstein, 1981).

10 ***ELISA assay:*** ELISA for determination of antigen-specific antibodies in mouse serum and in hybridoma supernatants were carried out as described (Coligan et al., 1994) using recombinant human IL-8 and TNF- α and affinity-purified EGFR from A431 cells (Sigma, E-3641) to capture the antibodies. The concentration of human and mouse immunoglobulins were determined using the following capture antibodies: rabbit anti-human IgG (Southern Biotechnology, 6145-01), goat 15 anti-human Ig κ (Vector Laboratories, AI-3060), mouse anti-human IgM (CGM/ATCC, HB-57), for human γ , κ , and μ Ig, respectively, and goat anti-mouse IgG (Caltag, M 30100), goat anti-mouse Ig κ (Southern Biotechnology, 1050-01), goat anti-mouse IgM (Southern Biotechnology, 1020-01), and goat anti-mouse λ (Southern Biotechnology, 1060-01) to capture mouse γ , κ , μ , and λ Ig, respectively. The detection antibodies used in ELISA experiments were goat anti-mouse IgG-HRP 20 (Caltag, M-30107), goat anti-mouse Ig κ -HRP (Caltag, M 33007), mouse anti-human IgG2-HRP (Southern Biotechnology, 9070-05), mouse anti-human IgM-HRP (Southern Biotechnology, 9020-05), and goat anti-human kappa-biotin (Vector BA-3060). Standards used for quantitation of 25 human and mouse Ig were: human IgG γ (Calbiochem, 400122), human IgM κ (Cappel, 13000), human IgG κ (Calbiochem, 400122), mouse IgG κ (Cappel 55939), mouse IgM κ (Sigma, M-3795), and mouse IgG λ (Sigma, M-9019).

25 ***Determination of affinity constants of fully human Mabs by BIACore:*** Affinity measurement of purified human monoclonal antibodies, Fab fragments, or hybridoma supernatants by plasmon resonance was carried out using the BIACore 2000 instrument, using general procedures

outlined by the manufacturers

Kinetic analysis of the antibodies was carried out using antigens immobilized onto the sensor surface at a low density: human IL-8 -81 RU, soluble EGFR purified from A431 cell membranes (Sigma, E-3641)- 303 RU, and TNF- α - 107 RU (1,000 RU correspond to about 1 ng/mm² of immobilized protein). The dissociation (kd) and association (ka) rates were determined using the software provided by the manufacturers, BIAevaluation 2.1.

Affinity measurement by radioimmunoassay: ^{125}I -labeled human IL-8 (1.5×10^{-11} M or 3×10^{-11} M) was incubated with purified anti-IL-8 human antibodies at varying concentrations (5×10^{-13} M to 4×10^{-9} M) in 200 μl of PBS with 0.5% BSA. After 15 hrs. incubation at room temperature, 20 μl of Protein A Sepharose CL-4B in PBS (1/1, v/v) was added to precipitate the antibody-antigen complex. After 2 hrs. incubation at 4°C, the antibody- ^{125}I -IL-8 complex bound to Protein A Sepharose was separated from free ^{125}I -IL-8 by filtration using 96-well filtration plates (Millipore, Cat. No. MADVN65), collected into scintillation vials and counted. The concentration of bound and free antibodies was calculated and the binding affinity of the antibodies to the specific antigen was obtained using Scatchart analysis (2)

Receptor binding assays: The IL-8 receptor binding assay was carried out with human neutrophils prepared either from freshly drawn blood or from buffy coats as described (Lusti-Marasimhan et al., 1995). Varying concentrations of antibodies were incubated with 0.23 nM [^{125}I]IL-8 (Amersham, IM-249) for 30 min at 4°C in 96-well Multiscreen filter plates (Millipore, MADV N6550) pretreated with PBS binding buffer containing 0.1% bovine serum albumin and 0.02% NaN₃ at 25°C for 2 hours. 4×10^5 neutrophils were added to each well, and the plates were incubated for 90 min at 4°C. Cells were washed 5 times with 200 μl of ice-cold PBS, which was removed by aspiration. The filters were air-dried, added to scintillation fluid, and counted in a scintillation counter. The percentage of specifically bound [^{125}I]IL-8 was calculated as the mean cpm detected in the presence of antibody divided by cpm detected in the presence of buffer only.

Binding assays for TNF receptor were performed in a similar manner as the IL-8 assays described above. However, the human monocyte line U937 was utilized instead of the neutrophil line

used in connection with the IL-8 assays. Antibodies were preincubated with 0.25 nM [¹²⁵I]TNF (Amersham, IM-206) 5 x 10⁴ U937 cells were placed in each well.

The EGFR receptor binding assay was carried out with A431 cells (0.4 x 10⁴ cells per well) which were incubated with varying concentrations of antibodies in PBS binding buffer for 30 minutes 5 at 4°C. 0.1 nM [¹²⁵I]EGF (Amersham, IM-190) was added to each well, and the plates were incubated for 90 min at 4°C. The plates were washed five times, air-dried and counted in a scintillation counter. Anti-EGFR mouse antibodies 225 and 528 (Calbiochem) were used as controls.

Repertoire analysis of human Ig transcripts expressed in XenoMice and their derived

10 *human Mabs:* Poly(A⁺) mRNA was isolated from spleen and lymph nodes of unimmunized and immunized XenoMice using a Fast-Track kit (Invitrogen). The generation of random primed cDNA was followed by PCR. Human V_H or human V_K family specific variable region primers (Marks et al., 1991) or a universal human V_H primer, MG-30 (CAGGTGCAGCTGGAGCAGTCIGG) was used in conjunction with primers specific for the human C_H (huP2) or C_K (hKp2) constant regions as 15 previously described (Green et al., 1994), or the human γ 2 constant region MG-40d, 5'-GCTGAGGGAGTAGAGTCCTGAGGA-3'. PCR products were cloned into pCRII using a TA cloning kit (Invitrogen) and both strands were sequenced using Prism dye-terminator sequencing kits and an ABI 377 sequencing machine. Sequences of human Mabs-derived heavy and kappa chain 20 transcripts were obtained by direct sequencing of PCR products generated from poly(A⁺) RNA using the primers described above. All sequences were analyzed by alignments to the "V BASE sequence directory" (Tomlinson et al., MRC Centre for Protein Engineering, Cambridge, UK) using MacVector and Geneworks software programs.

25 *Preparation and purification of antibody Fab fragments:* Antibody Fab fragments were produced by using immobilized papain (Pierce). The Fab fragments were purified with a two step chromatographic scheme. HiTrap (Bio-Rad) Protein A column to capture Fc fragments and any undigested antibody, followed by elution of the Fab fragments retained in the flow-through on strong cation exchange column (PerSeptive Biosystems), with a linear salt gradient to 0.5 M NaCl. Fab fragments were characterized by SDS-PAGE and MALDI-TOF MS under reducing and non-reducing

conditions, demonstrating the expected ~50 kD unreduced fragment and ~25 kDa reduced doublet. This result demonstrates the intact light chain and the cleaved heavy chain. MS under reducing conditions permitted the unambiguous identification of both the light and cleaved heavy chains since the light chain mass can be precisely determined by reducing the whole undigested antibody.

5

EXAMPLES

The following examples, including the experiments conducted and results achieved are provided for illustrative purposes only and are not to be construed as limiting upon the present invention.

10

Example 1: Reconstruction of human heavy chain loci on YACs

In accordance with the present invention, the strategy that we utilized to reconstruct the human heavy chain and human kappa light chain variable regions was to, first, screen human-YAC libraries for YACs that spanned the large (megabase-sized) human Ig loci and, second, to recombine YACs spanning such regions into single YACs containing the desired loci predominantly in germline configuration.

The above, stepwise, YAC recombination scheme exploited the high frequency of meiotic-induced homologous recombination in yeast and the ability to select the desired recombinants by the yeast markers present on the vector arms of the recombined YACs (See Figure 1, and Green et al., *supra*, see also Silverman et al., 1990 and denDunnen et al., 1992).

In connection with our strategy, we identified four YACs, 1H (240 kb), 2H (270 kb), 3H (300 kb), and 4H (340 kb), which spanned about 830 kb, out of the about 1000 kb, of the human heavy chain variable region on chromosome 14q. YACs 1H, 2H, 3H, and 4H were used for reconstruction of the locus (See Figure 1A). Pulsed Field Gel Electrophoresis (PFGE) and Southern blot analysis confirmed the YACs to be in intact, germline configuration, with the exception of 150 kb at the 3' end of YAC 2H which contained certain non-IgH sequences (See Figure 1, Matsuda et al., 1990). YAC 1H, the YAC that was previously introduced into our first generation XenoMouse™ (Green et al., *supra*, Mendez et al., 1995), is comprised of the human C_δ, C_μ, J_μ, and D_μ regions and the first 5 V_μ genes in germline configuration. The other three YACs cover the majority of the V_μ region, from

V_H2-5 to V_H3-65, thus contributing approximately an additional 31 different V_H genes. Prior to recombination, YAC 4H was retrofitted with an HPRT selectable marker. Through utilization of the overlapping sequences contained on the YACs, the four YACs (1H, 2H, 3H, and 4H) were recombined in yeast by a stepwise recombination strategy (See Figure 1A). Such recombination strategy generated a 980 kb recombinant YAC (See Figure 1). Analysis of the YAC by PFGE and Southern blot analysis confirmed the presence of the human heavy chain locus from the C₃ region to 20 kb 5' of the V_H3-65 gene in germline configuration. No apparent deletions or rearrangements were observed.

The YAC acentric arm was targeted with a vector bearing the complete human γ 2 constant region, mouse 3' enhancer, and the neomycin resistance gene, to yield the final 1020 kb heavy chain YAC, yH2. YAC yH2 contained the majority of the human variable region i.e., 66 out of the 82 V_H genes, complete D_H (32 genes), and J_H (6 genes) regions and three different constant regions (C μ , C δ , and C γ) with their corresponding regulatory sequences (See Figure 1A). This was the heavy chain construct utilized for the production of our XenoMouse II strains

15

Example 2: Reconstruction of human kappa light chain loci on YACs

A similar stepwise recombination strategy was utilized for reconstruction of the human kappa light chain locus. Three YACs were identified that spanned the human kappa loci. The YACs were designated 1K, 2K and 3K. YAC 1K, which had a length of approximately 180 kb, had previously been introduced into our first generation XenoMouseTM. Such YAC contained the kappa deleting element, (Kde), the kappa 3' and intronic enhancers, C₃, J₃, and the three V_k genes on the B cluster (Green et al., 1994; Mendez et al., 1995). YAC 2K (approximately 480 kb), and 3K (approximately 380 kb) together encompass most of the kappa chain proximal variable region on chromosome 2p. A deletion of approximately 100 kb spans the L13-L5 region (Fig. 1B, Huber et al., 1993). Inasmuch as the kappa distal region duplicates the proximal region, and as the proximal V_k genes are the ones most commonly utilized humans (Weichold et al., 1993, Cox et al., 1994), the proximal region was the focus of our reconstruction strategy (Fig. 1B). Through homologous recombination of the three YACs, an 800 kb recombinant YAC, yK2, was recovered. The size and integrity of the recombinant YAC was confirmed by PFGE and Southern blot analysis. Such analysis demonstrated that it covered

the proximal part of the human kappa chain locus, with 32 V_{κ} genes in germline configuration except for the described deletion in the Lp region (Fig. 1B). γ K2 centric and acentric arms were modified to contain the HPRT and neomycin selectable markers, respectively, as described (Materials and Methods). This was the kappa light chain construct utilized for the production of our XenoMouse 5 II strains.

The YACs described herein, γ H2 and γ K2, represent the first megabase-sized reconstructed human Ig loci to contain the majority of the human antibody repertoire, predominantly in germline configuration. This accomplishment further confirmed homologous recombination in yeast as a powerful approach for successful reconstruction of large, complex, and unstable loci. The selection 10 of stable YAC recombinants containing large portions of the Ig loci in yeast provided us with the human Ig fragments required to equip the mice with the human antibody repertoire, constant regions, and regulatory elements needed to reproduce human antibody response in mice.

Example 3: Introduction of γ H2 and γ K2 YACs into ES cells

15 In accordance with our strategy, we introduced the YACs, γ H2 and γ K2, into mouse embryonic stem (ES) cells. Once ES cells containing the YAC DNA were isolated, such ES cells were utilized for the generation of mice through appropriate breeding.

In this experiment, therefore, YACs γ H2 and γ K2, were introduced into ES cells via fusion 20 of YAC-containing yeast spheroplasts with HPRT-deficient E14 TG3B1 mouse ES cells as previously described (Jakobovits et al., 1993a; Green et al., 1994). HPRT-positive ES cell clones were selected at a frequency of 1 clone/15-20 \times 10⁶ fused cells and were analyzed for YAC integrity by Southern and CHEF blot analyses (Fig. 2A).

25 Seven of thirty-five ES cell clones (referred to as L10, J9 2, L17, L18, J17, L22, L23) derived from ES cell fusion with γ H2-containing yeast were found to contain all expected EcoRI and BamHI γ H2 fragments detected by probes spanning the entire insert: mouse 3' enhancer, human intronic enhancer, human C $_{\gamma}$ 2, C $_{\delta}$, and C $_{\mu}$ constant regions, D $_{\text{H}}$, J $_{\text{H}}$ and all the different V $_{\text{H}}$ families: V $_{\text{H}}$ 1, V $_{\text{H}}$ 2, V $_{\text{H}}$ 3, V $_{\text{H}}$ 4, V $_{\text{H}}$ 5, and V $_{\text{H}}$ 6 (data shown for 5 clones in Fig. 2A). CHEF analysis further confirmed that these clones, which represent 20% of all clones analyzed, contain the entire intact γ H2 YAC with no apparent deletions or rearrangements (data not shown).

ES cell clones derived from the fusion of yK2-containing yeast were similarly analyzed for YAC integrity, using probes specific for the human Kde, kappa Y and intronic enhancers, C₁, C₂ and all of the different V₁ families V₁I, V₁II, V₁III, V₁IV, V₁VI. Twenty clones of the sixty clones had intact and unaltered YAC, which represent 33% of total clones analyzed (data shown for two ES 5 clones in Fig. 3A). Varying amounts of yeast genomic sequences were detected in yH2 and yK2-ES cell clones (data not shown).

These results are the first demonstration of introduction of megabase-sized constructs encompassing reconstructed human loci, predominantly in germline configuration, into mammalian cells. The relatively high frequency of intact YACs integrated into the mouse genome further 10 validated the ES cell-yeast spheroplast fusion methodology as an effective approach for faithful introduction of large human genomic fragments into ES cells.

Example 4: Generation of XenoMouse II strains

In order to generate mice from the YAC DNA containing ES cells, microinjection of 15 blastocysts was conducted, followed by breeding. Thus, yH2- and yK2-bearing ES cell clones were expanded and microinjected into mouse C57BL/6J blastocysts (Green et al., 1994) and the chimeric males produced were evaluated for germline transmission. Offspring with transmitted YAC were identified by PCR analysis and the YAC integrity was confirmed by Southern blot analysis. In all transgenic mice analyzed the YAC was shown to be in intact form (Fig 2B, 3B). All seven 20 microinjected yH2-ES clones and two out of eight yK2-ES clones were transmitted through the mouse germline.

In order to generate mice that produced human antibodies to the exclusion of endogenous antibodies, yH2- or yK2-transgenic mice were bred with double-inactivated (DI) mouse strains. The DI mouse strains are homozygous for gene targeted-inactivated mouse heavy and kappa chain loci and thus are deficient in antibody production (Jakobovits et al., 1993b; Green et al., 1994). Two of the yH2- transgenic mouse strains L10 and J9.2, and one of the yK2-transgenic mouse strains, J23.1, 25 were bred with DI mice to generate mice bearing YACs on an homozygous inactivated mouse heavy and kappa chain background (yH2,DI, and yK2,DI). Each of the yH2,DI transgenic strains were bred with the yK2,DI transgenic strain to generate two XenoMouse II strains, 2A-1 (L10,J23.1,DI) and

2A-2 (J9.2, J23.1, DI), respectively, containing both heavy and light chain YACs on homozygous DI background. L10 is fully homozygous and J9.2 and J23.1 are in the process of being successfully bred to homozygosity.

The integrity of the human heavy and kappa chain YACs in XenoMouse II strains was confirmed by Southern blot analysis. As shown in Fig. 2 and Fig. 3, in both XenoMouse strains analyzed, yH2 and yK2 were transmitted unaltered through multiple generations with no apparent deletions or rearrangements.

Example 5: B-cell development and human antibody production by XenoMouse II mice

In order to further characterize the XenoMouse II strains, we studied their B-cell development and their production of human antibodies. Reconstitution of B-cell development and antibody production in XenoMouse II strains by yH2 and yK2 YACs was evaluated by flow cytometry and ELISA. In contrast to DI mice, which completely lack mature B-cells, XenoMouse II manifested essentially normal B-cell development with the mature B-cell population in the blood totaling over 50% of the level seen in wild type mice (Fig. 4A). All B-cells were shown to express human IgM and high levels of B220 (human IgM⁺/B220^{hi}), with 60% of this population also expressing human IgD. Similar results were obtained from analysis of XenoMouse spleen and lymph nodes (not shown). These results correlate well with the characteristics of mature B-cells in wild type mice, indicating proper B-cell maturation in XenoMouse.

The majority of XenoMouse B-cells (75-80%) expressed exclusively human kappa (κ) light chain, whereas only about 15% expressed mouse lambda (λ) light chain (Fig. 4). This light chain distribution ratio (hκ/mλ, 75/15) is comparable to that observed in wild type mice, indicating a mouse-like regulation of light chain utilization. In contrast, XenoMouse I, as described in Green et al., 1994, showed a ratio of hκ/mλ, 55/45 (data not shown). Similar observations were made for B-cells from spleen (Fig. 4B) and lymph nodes (not shown), indicating that most of XenoMouse II's B-cells produced exclusively fully human antibodies. Levels of mλ-expressing B-cells were reduced from 15% to 7% in XenoMouse II strains homozygous for yK2 (data not shown).

Example 6: Generation of L6 Strain

The L6 strain of mice were generated identically to the process described above in connection with the generation of the XenoMouse II strains. However, owing to a deletion event during the generation of the L6 ES cell line, the ES cell line, and, subsequently, the L6 mouse evolved without a portion of the sequence distal to C δ , thus, eliminating the C γ constant region and its regulatory sequences. Following completion of breeding, the L6 mice will contain the entire yK2 construct and the entire yH2 construct, except for the missing C γ constant region.

10 *Example 7: Human Antibody Production*

Expression of human C μ , C γ 2, and κ light chains were detected in unimmunized XenoMouse II sera at maximal levels of 700, 600, and 800 μ g/ml, respectively. To determine how these values compared to wild-type, we measured maximal levels of mouse C μ , C γ 2, and κ light chains in C57BL/6J x 129 mice kept under similar pathogen-free conditions. The values for C μ , C γ 2, and κ light chain in wild-type mice were 400, 2000, and 2000 μ g/ml, respectively. Upon immunization, the human γ chain levels increased to approximately 2.5 mg/ml. The concentration of mouse λ was only 70 μ g/ml, further confirming the preferential use of human kappa chain.

15 These findings confirmed the ability of the introduced human Ig YACs to induce proper Ig gene rearrangement and class switching and to generate significant levels of fully human IgM and IgG 20 antibodies before and after immunization.

Example 8: A diverse human antibody repertoire in XenoMouse II

In order to further understand the reconstitution of the antibody repertoire in XenoMouse II strains, we challenged mice with several antigens, and prepared hybridoma cell lines secreting such 25 antibodies. As will be understood, recapitulation of the human antibody response in mice requires diverse utilization of the different human variable genes contained on yH2 and yK2 YACs. The diversity of the human antibodies generated by XenoMouse II strains was determined by cloning and sequencing human heavy chain (μ and γ) and kappa light chain transcripts from XenoMouse lymph nodes. Based upon our data to date, sequence analysis demonstrates that XenoMouse II utilizes at

least 11 out of the 37 functional V_{H2} genes present on γ H2, eight different D_{H2} segments and three J_{H2} genes (J_{H3} , J_{H4} , J_{H6}) (Table III, J_{H5} was also detected in connection with our sequencing antibodies from hybridomas) V -D-J sequences were linked to human μ or $\gamma 2$ constant regions (not shown)

The V_{H2} genes utilized are widely distributed over the entire variable region and represent four out of the seven V_{H2} families (Table III). The predominant utilization of V genes from V_{H3} and V_{H4} families is similar to the V_{H2} usage pattern in adult humans, which is proportional to family size (Yamada et al., 1991; Brezinshek et al., 1995). The predominant usage of J_{H4} is also reminiscent of that detected in human B-cells (Brezinshek et al., 1995). Addition of non-germline nucleotides (N-additions) at both V-D and D-J joinings, ranging from 1-12 bp, were also observed. Such N-additions produced complementary determining regions 3 (CDR3s) with lengths of from 8 to about 19 amino acid residues, which is very comparable to that observed in adult human B-cells (Yamada et al., 1991; Brezinshek et al., 1995). Such CDR3 lengths observed in the XenoMouse II are much longer than CDR3 lengths ordinarily observed in mice (Feeny, 1990).

A highly diverse repertoire was also found in the ten kappa chain transcripts sequenced. In addition to displaying 8 out of the 25 $V\kappa$ functional open reading frames (ORFs) present on γ K2, all of the $J\kappa$ genes were detectable (Table IV). The different $V\kappa$ genes utilized were widely dispersed throughout γ K2, representing all four major $V\kappa$ gene families. All $V\kappa$ - $J\kappa$ recombination products were linked properly to $C\kappa$ sequences. The paucity of N-additions in our transcripts is in agreement with the greatly reduced terminal deoxynucleotide transferase activity at the stage of kappa chain rearrangement. The average CDR3 length of 9-10 amino acids that we observed in the kappa chain transcripts is identical to that observed in human B-cells (Marks et al., 1991).

In Tables III and IV below, repertoire analyses of human heavy and kappa light chain transcripts expressed in XenoMouse II strains are presented. Human μ , γ , and κ specific mRNAs were amplified by PCR, cloned and analyzed by sequencing as described in Materials and Methods. Table III shows a series of nucleotide sequences of 12 unique human heavy chain clones, divided into V_{H2} , D , J_{H2} and N segments, as identified by homology with published germline sequences (Materials and Methods). Each D segment assignment is based on at least 8 bases of homology. Table IV shows a series of nucleotide sequences of V-J junctions of 3 independent human κ clones. The sequences are divided into V_{κ} , J_{κ} and N segments and identified based on homology to published V_{κ}

and λ sequences. In each of the Tables N-additions and deletions (indicated as) were determined by their lack of sequence homology to V, D, or J sequences.

5 TABLE III
Repertoire Analysis of Human Heavy Chain Transcripts

Clone	V _h	I	N	D _h	I	N	I	J _h
A2.2.1	5-51 (DP73) TTACTCTGGAGAGA	4 TAGC	1	XPS ₁₀ ATCAT		12 GGGACCTACGGG		JH4 <u> </u> GACTACTGGGG
B2.1.5	3-33 (DP49) TTACTCTGGAGAGA				3 ₁ ATAGCA			JH4 <u> </u> CTTGACTACTGGGG
10 B4.2.4	3-15 (DP38) TTACTGTACCAAGA	1 (G)		K1 GGCTAC		11 GACTAACTACCC		JH6 <u> </u> CTACTACTACTAGGT
B4.2.5	4-19 (DP7) TTACTCTGGAGAGA	10 TAGGACTCTT		4 GTAGTACCAAGCTGTAT		6 ACCCAA		JH6 <u> </u> ACTACTACTACTACGGT
D2.2.5	4-34 (DP63) TTACTCTGGAGAGA	2 GG		N1 GCACCACTC		4 CCCT		JH4 <u> </u> CTTGACTACTGGGG
D2.1.3	3-48 (DP51) TTACTCTGGAGAGA	4 TCCT		XPI GATATTTGACTGOT		2 (CT)		JH6 <u> </u> CTACTACTACTACGGT
15 D2.2.8	4-21 (DP65) TTACTCTGGAGAGA	2 (GA)		43 GACTGCAG		5 CCGTT		JH4 <u> </u> CTTGACTACTGGGG
A2.2.4	3-21 (DP77) TTACTCTGGAGAGA	2 TT		IR3 GGGGCTTC		3 ACC		JH6 <u> </u> TACTACTACTACTACGGT
B4.2.11	4-44.35 ATTACTCTGGAGAGA	3 (A)		N1 TATACCAAGCTGCTGCT		2 (CT)		JH4 <u> </u> CTTGACTACTGGGG
C1.2.1	3-18 (DP14) TATTACTCTGGAGAGA	0		XPI 21.7 GTTA		0		JH4 <u> </u> GACTACTGGGG
C3.1.2	4-39 (DP79) TATTACTCTGGAGAGA	3 GCC		2 GGATATGACTGCG		6 CTCGGG		JH4 <u> </u> CTTGACTACTGGGG
20 D2.2.7	5-51 (DP73) TTACTCTGGAGAGA	4 TCGG		K1 AGTGGCT		9 GGTACTCTG		JH3 ATGCCTTGATATCTGGGG

TABLE IV
Repertoire Analysis of Human Kappa Light Chain Transcripts

Clone	V _k	N	J _k
5	02 (DPK9) TTAAACGAAACAGTACCCC	0	J _{k5} GATCACCTTCGGCAA
	LS (DPK5) ACAGGCTAACACTTCCCTC	0	J _{k1} GGACGTTGGCAA
	A20 (DPK4) AAGTATAAACAGTCCCC	0	J _{k3} ATTCACTTTGGCCCT
	08 ACAGTATGATAATCTCCC	0	J _{k4} GCTCACTTTGGCGGA
	LI AAAGTATAATAGTTACCC	0	J _{k5} GATCACCTTCGGCAA
10	A30 CAGCATAATAGTTACCC	0	J _{k3} ATTCACTTTGGCCCT
	B3 (DPK24) AATATTATAGTACTCC	0	J _{k4} GCTCACTTTGGCGGA
	A27 (DPK22) CACTATGGTAGCTCACCTC	1 (G)	J _{k2} CACTTTGCCAG

15 These results, together with sequences of XenoMouse-derived hybridomas described later, demonstrate a highly diverse, adult human-like utilization of V, D, and J genes, which appears to demonstrate that the entire human heavy and kappa chain variable regions present on the yH2 and the yK2 YACs are accessible to the mouse system for antibody rearrangement and are being utilized in a non-position-biased manner. In addition, the average length of N-additions and CDR3s for both 20 the heavy and kappa chain transcripts, is very similar to that seen in adult human B-cells, indicating that the YAC DNA contained in the mice direct the mouse machinery to produce an adult human-like immune repertoire in mice.

25 In connection with the following Examples, we prepared high affinity antibodies to several antigens. In particular, antigens were prepared to human IL-8 and human EGFR. The rationale for the selection of IL-8 and EGFR is as follows

IL-8 is a member of the C-X-C chemokine family. IL-8 acts as the primary chemoattractant for neutrophils implicated in many diseases, including ARDS, rheumatoid arthritis, inflammatory bowel disease, glomerulonephritis, psoriasis, alcoholic hepatitis, reperfusion injury, to name a few.

Moreover, IL-8 is a potent angiogenic factor for endothelial cells. In Figures 22-28, we demonstrate that human anti-IL-8 antibodies derived from XenoMouse II strains are effective in inhibiting IL-8's actions in a number of pathways. For example, Figure 22 shows blockage of IL-8 binding to human neutrophils by human anti-IL-8. Figure 23 shows inhibition of CD11b expression on human neutrophils by human anti-IL-8. Figure 24 shows inhibition of IL-8 induced calcium influx by human anti-IL-8 antibodies. Figure 25 shows inhibition of IL-8 R_B/C_B chemotaxis by human anti-IL-8 antibodies. Figure 26 is a schematic diagram of a rabbit model of human IL-8 induced skin inflammation. Figure 27 shows the inhibition of human IL-8 induced skin inflammation in the rabbit model of Figure 26 with human anti-IL-8 antibodies. Figure 28 shows inhibition of angiogenesis of endothelial cells on a rat corneal pocket model by human anti-IL-8 antibodies.

EGFR is viewed as an anti-cancer target. For example, EGFR is overexpressed, up to 100 fold, on a variety of cancer cells. Ligand (EGF and TNF) mediated growth stimulation plays a critical role in the initiation and progression of certain tumors. In this regard, EGFR antibodies inhibit ligand binding and lead to the arrest of tumor cell growth, and, in conjunction with chemotherapeutic agents, induces apoptosis. Indeed, it has been demonstrated that a combination of EGFR Mabs resulted in tumor eradication in murine xenogeneic tumor models. Imclone has conducted Phase I clinical utilizing a chimeric Mab (C225) that proved to be safe. In Figures 31-33, we demonstrate data related to our human anti-EGFR antibodies. Figure 30 shows heavy chain amino acid sequences of human anti-EGFR antibodies derived from XenoMouse II strains. Figure 31 shows blockage EGF binding to A431 cells by human anti-EGFR antibodies. Figure 32 shows inhibition of EGF binding to SW948 cells by human anti-EGFR antibodies. Figure 33 shows that human anti-EGFR antibodies derived from XenoMouse II strains inhibit growth of SW948 cells *in vitro*.

Example 9: High affinity, antigen-specific human Mabs produced by XenoMouse II

We next asked whether the demonstrated utilization of the large human repertoire in XenoMouse II could be harnessed to generate human antibodies to multiple antigens, in particular, human antigens of significant clinical interest.

Accordingly, individual XenoMouse II pups were challenged each with one of three different antigen targets, human IL-8, human EGFR and human TNF- α . Antigens were administered in two

different forms, either as soluble protein, in the case of IL-8 and TNF- α or expressed on the surface of cells (A431 cells), in the case of EGFR. For all three antigens, ELISAs performed on sera from immunized mice indicated a strong antigen-specific human antibody (IgG, Ig κ) response with titers as high as 1.3×10^9 . Negligible mouse Ig κ response was detected

5 Hybridomas were derived from spleen or lymph node tissues by standard hybridoma technology and were screened for secretion of antigen-specific human Mabs by ELISA.

An IL-8 immunized XenoMouse II yielded a panel of 12 hybridomas, all secreting fully human (hIgG κ) Mabs specific to human IL-8. Antibodies from four of these hybridomas, D1.1, K2.2, K4.2, and K4.3, were purified from ascitic fluid and evaluated for their affinity for human IL-8 and their 10 potency in blocking binding of IL-8 to its receptors on human neutrophils.

Affinity measurements were performed by solid phase measurements of both whole antibody and Fab fragments using surface plasmon resonance in BLAcore and in solution by radioimmunoassay (Materials and Methods). As shown in Table V, affinity values measured for the four Mabs ranged from 1.1×10^9 to 4.8×10^{10} M $^{-1}$. While there was some variation in the techniques employed, affinity 15 values for all four antibodies were consistently higher than 10^9 M $^{-1}$.

ELISA analysis confirmed that these four antibodies were specific to human IL-8 and did not cross-react with the closely related chemokines MIP-1 α , GRO α , β , and γ , ENA-78, MCP-1, or RANTES (data not shown). Further, competition analysis on the BLAcore indicated that the 20 antibodies recognize at least two different epitopes (data not shown). All antibodies inhibit IL-8 binding to human neutrophils as effectively as the murine anti-human IL-8 neutralizing antibody, whereas a control human IgG κ antibody did not (Fig. 5A).

Fusion experiments with EGFR-immunized XenoMouse II yielded a panel of 25 hybridomas, all secreting EGFR-specific human IgG κ Mabs. Of the thirteen human Mabs analyzed, four (E2.1, E2.4, E2.5, E2.11) were selected for their ability to compete with EGFR-specific mouse antibody 25 225, which has previously been shown to inhibit EGF-mediated cell proliferation and tumor formation in mice (Sato et al., 1983). These human antibodies, purified from ascitic fluid, were evaluated for their affinity for EGFR and neutralization of EGF binding to cells. The affinities of these antibodies for EGFR, as determined by BLAcore measurements, ranged from 2.9×10^9 to 2.9×10^{10} M $^{-1}$ (Table V). All four anti-EGFR antibodies completely blocked EGF binding to A431 cells (Fig. 5B).

demonstrating their ability to neutralize its binding to both high and low affinity receptors on these cells (Kawamoto et al., 1983). Complete inhibition of EGF binding to EGFR expressed on human SW945 human lung carcinoma cells by all four anti-EGFR human antibodies was also observed (data not shown). In both cases, the fully human antibodies were as effective in inhibition of EGF binding as the anti-EGFR mouse antibody, 225 and more potent than the 518 antibody (Gill et al., 1983). In both cell assays, a control human IgG₁ antibody did not affect EGF binding (Fig. 5B and data not shown).

10 Fusion experiments with TNF- α immunized Xenomouse II yielded a panel of 12 human IgG₁ antibodies. Four out of the 12 were selected for their ability to block the binding of TNF- α to its receptors on U937 cells (Fig. 5C). The affinities of these antibodies were determined to be in the range of 1.2-3.9x10⁹ M⁻¹ (Table V).

15 The described Xenomouse-derived hybridomas produced antibodies at concentrations in the range of 2-19 μ g/ml in static culture conditions. Characterization of the purified antibodies on protein gels under non-reducing conditions revealed the expected apparent molecular weight of 150 kD for the IgG₁ antibody. Under reducing conditions the expected apparent molecular weights of 50 kD for the heavy and 25 kD for the light chain were detected (data not shown).

20 Table V, below, shows affinity constants of XenoMouse-derived antigen-specific fully human Mabs. The affinity constants of XenoMouse-derived human IgG₁ Mabs specific to IL-8, EGFR, and TNF- α were determined by BIACore or by radioimmunoassay as described in Materials and Methods. The values shown for IL-8 and EGFR are representative of independent experiments carried out with purified antibodies, while the values shown for TNF- α are from experiments carried out with hybridoma supernatants.

TABLE V

Human Mab IgG. κ	Antigen	k_a ($M^{-1}S^{-1}$)	k_d (S^{-1})	K_A (M^{-1})	K_D (M)	Surface Density (RU)	Radio immunoassay (M^{-1})
Solid Phase Measurements							
D1.1	IL-8	2.7×10^6	9.9×10^4	2.7×10^9	3.7×10^{-10}	81	2.0×10^{10}
D1.1 Fab	IL-8	2.1×10^6	2.1×10^3	1.1×10^9	8.8×10^{-10}	81	4.9×10^{11}
K2.2	IL-8	0.9×10^6	2.3×10^4	4.0×10^9	2.5×10^{-10}	81	1.0×10^{10}
K4.2	IL-8	2.5×10^6	4.1×10^4	6.3×10^9	1.6×10^{-10}	81	ND
K4.3	IL-8	4.3×10^6	9.4×10^4	4.5×10^9	2.2×10^{-10}	81	2.1×10^{11}
K4.3 Fab	IL-8	6.0×10^6	2.1×10^3	2.9×10^9	3.4×10^{-10}	81	
ELISA (M)							
E1.1	EGFR	1.9×10^6	6.5×10^4	2.9×10^9	3.46×10^{-10}	303	1.1×10^{10}
E2.5	EGFR	2.1×10^6	1.8×10^4	1.2×10^9	8.44×10^{-11}	303	3.6×10^{10}
E2.11	EGFR	1.7×10^6	4.7×10^4	3.7×10^9	2.68×10^{-10}	303	1.1×10^{10}
E2.4	EGFR	2.8×10^6	9.78×10^3	2.9×10^9	3.5×10^{-11}	818	1.1×10^{10}
T22.1	TNF- α	1.6×10^6	1.3×10^3	1.2×10^9	8.06×10^{-10}	107	
T22.4	TNF- α	2.4×10^6	4.6×10^4	5.3×10^9	1.89×10^{-10}	107	
T22.8	TNF- α	1.7×10^6	7.5×10^4	2.3×10^9	4.3×10^{-10}	107	
T22.9	TNF- α	2.3×10^6	4.9×10^4	4.8×10^9	2.11×10^{-10}	107	
T22.11	TNF- α	2.9×10^6	7.9×10^4	N/A	2.76×10^{-10}	107	

Example 10: Gene usage and somatic hypermutation in monoclonal antibodies

The sequences of the heavy and kappa light chain transcripts from the described IL-8 and EGFR-human Mabs were determined Figure 6 and Figures [[]]. The four IL-8-specific antibodies consisted of at least three different V_H genes ($V_{H4.4}$, $V_{H4.2b}$, $V_{H3.30}$ and $V_{H5.2}$), four different D_H segments (A1/A4, K1, ir3rc, and 21-10rc) and two J_H (J_{H2} and J_{H4}) gene segments. Three different V_K genes (012, 018, and B3) combined with J_K3 and J_K4 genes. Such diverse utilization shows that

Xenomouse II is capable of producing a panel of anti-IL-8 neutralizing antibodies with diverse variable regions

In contrast to the IL-8 antibody transcripts, the sequences of antibodies selected for their ability to compete with Mab 225 showed relatively restricted V_H and V_K gene usage, with three antibodies, E1 1, E2 4 and E2 5 sharing the same V_H gene (4-31) and E2 11 containing V_{H4-31} , which is highly homologous to V_{H4-31} . Different D (2, A1, A4, XP1) and J $_H$ (J $_{H3}$, J $_{H4}$, J $_{H5}$) segments were detected. All four antibodies were shown to share the same V_K (018) gene. Three of them contained J κ 4, and one, E2 5, contained J κ 2.

Most V_H and V_K hybridoma transcripts showed extensive nucleotide changes (7-17) from the corresponding germline segments, whereas no mutations were detected in the constant regions. Most of the mutations in V segments resulted in amino acid substitutions in the predicted antibody amino acid sequences (0-12 per V gene), many in CDR1 and CDR2 regions (Figure 2). Of note are the mutations which are shared by the heavy chain sequences of EGFR antibodies, such as the Gly-Asp substitution in CDR1, shared by all antibodies, or Ser-Asn substitution in CDR2 and Val-Leu in the framework region 3 shared by three antibodies. These results indicated that an extensive process of somatic hypermutation, leading to antibody maturation and selection, is occurring in Xenomouse II.

Discussion

This present application describes the first functional substitution of complex, megabase-sized mouse loci, with human DNA fragments equivalent in size and content reconstructed on YACs. With this approach, the mouse humoral immune system was "humanized" with megabase-sized human Ig loci to substantially reproduce the human antibody response in mice deficient in endogenous antibody production.

Our success in faithful reconstruction of a large portion of the human heavy and kappa light chain loci, nearly in germline configuration, establishes YAC recombination in yeast as a powerful technology to reconstitute large, complex and unstable fragments, such as the Ig loci (Mendez et al., 1995), and manipulate them for introduction into mammalian cells. Furthermore, the successful introduction of the two large heavy and kappa light chain segments into the mouse germline in intact form confirms the methodology of ES cell-yeast spheroplast fusion as a reliable and efficient approach.

to delivering xenogeneic loci into the mouse germline

Characterization of Xenomouse II strains has shown that the large Ig loci were capable of restoring the antibody system, comparable in its diversity and functionality to that of wildtype mice, and much superior to the humoral response produced in mice bearing human Ig minigene constructs (Lonberg et al., 1994) or small human Ig YACs (Green et al., 1994). This difference was manifested in the levels of mature B-cells, human Ig production, class switching efficiency, diversity, preponderance of human Ig κ over murine Ig λ production, and magnitude of the human antibody response, and success in the generation of high affinity, antigen-specific monoclonal antibodies to multiple antigens.

10 The levels of mature B-cells and human antibodies in Xenomouse II are the highest yet reported for Ig-transgenic mice, representing a several-fold increase over the levels shown for previous mice and approaching those of wildtype mice. In particular, the levels of the human IgG were more than 100 fold higher than those reported for mice bearing minilocus Ig transgenes with human $\gamma 1$ gene (Lonberg et al., 1994). The more efficient class switching in Xenomouse II was likely 15 the result of the inclusion of the entire switch regions, with all of their regulatory elements, as well as the additional control elements on $\gamma H2$, which may be important to support and maintain proper class switching. The elevated levels of mature B-cells in Xenomouse II strains are likely to result from the higher rearrangement frequency and thus improved B-cell development in the bone marrow due to the increased V gene repertoire. B-cell reconstitution is expected to be even more pronounced 20 in XenoMouse II strains that are homozygous for the human heavy chain locus.

The ratio of human κ to mouse λ light chain expression by circulating B-cells provides a useful internal measure of the utilization of the transgenic kappa chain locus. Whereas in mice containing one allele of smaller Ig YACs, an approximately equal distribution of human κ and mouse λ was observed, a significant preponderance of human κ was detected in Xenomouse II strains. 25 Moreover, in animals homozygous for $\gamma K2$ possessed a κ/λ ratio that is identical to wild type mice. These observations together with the broad $V\kappa$ gene usage strongly suggest that the human proximal $V\kappa$ genes in the Xenomouse II are sufficient to support a diverse light chain response and are consistent with the bias toward proximal $V\kappa$ gene usage in humans (Cox et al., 1994).

Xenomouse II strains exhibited highly increased antibody diversity with V , D , and J genes

across the entire span of the loci accessed by the recombination mechanism and incorporated into mature antibodies. Once triggered by antigen binding, extensive somatic hypermutation occurs, leading to affinity maturation of the antibodies.

The utilization pattern of V, D, J genes in Xenomouse II also indicated they are available and utilized in a manner reminiscent of their utilization in humans, yielding an adult-like human antibody repertoire, which is different from the fetal-like, position-biased usage observed in Ig minigene-bearing mice (Taylor et al., 1992, Taylor et al., 1994, Tuillion et al., 1993). The broad utilization of many of the functional V_{μ} and V_{κ} genes together with the multiplicity of antigens recognized by the mice underscores the importance of the large V gene repertoire to successfully 10 reconstituting a functional antibody response.

The ultimate test for the extent of reconstitution of the human immune response in mice is the spectrum of antigens to which the mice will elicit an antibody response and the ease with which 15 antigen-specific high affinity Mabs can be generated to different antigens. Unlike mice engineered with smaller human Ig YACs or minigenes, which yielded to date only a limited number of antigen-specific human Mabs (Lonberg et al., 1994, Green et al., 1994, Fishwild et al., 1996), Xenomouse II generated Mabs to all human antigens tested to date. Xenomouse II strains mounted a strong human antibody response to different human antigens, presented either as soluble proteins or expressed on the surfaces of cells. Immunization with each of the three human antigens tested yielded a panel of 10-25 antigen-specific human IgG₁κ Mabs. For each antigen, a set of antibodies 20 with affinities in the range of 10^8 - 10^{10} M⁻¹ was obtained. Several measures were taken to confirm that the affinity values represent univalent binding kinetics rather than avidity: BIAcore assays with intact antibodies were carried out with sensor chips coated at low antigen density to minimize the probability of bivalent binding; for two antibodies, the assay was repeated with monovalent Fab fragments; some of the antibodies were also tested by solution radioimmunoassay. From the results 25 of these measurements, we conclude that antibodies with affinities in the range of 10^{10} M⁻¹ are readily attainable with the XenoMouse. The affinity values obtained for XenoMouse-derived antibodies are the highest to be reported for human antibodies against human antigens produced from either engineered mice (Lonberg et al., Fishwild et al., 1996) or from combinatorial libraries (Vaughan et al., 1996). These high affinities combined with the extensive amino acid substitution as a result of

somatic mutation in the V genes confirms that the mechanism of affinity maturation is intact in Xenomouse II and comparable to that in wildtype mice

These results show that the large antibody repertoire on the human Ig YACs is being properly exploited by the mouse machinery for antibody diversification and selection, and, due to the lack of immunological tolerance to human proteins, can yield high affinity antibodies against any antigen of interest, including human antigens. The facility with which antibodies to human antigens can be generated by the human immunoglobulin genes in these mice provides further confirmation that self tolerance at the B-cell level is acquired and not inherited.

The ability to generate high affinity fully human antibodies to human antigens has obvious practical implications. Fully human antibodies are expected to minimize the immunogenic and allergic responses intrinsic to mouse or mouse-derivatized Mabs and thus to increase the efficacy and safety of the administered antibodies. Xenomouse II offers the opportunity of providing a substantial advantage in the treatment of chronic and recurring human diseases, such as inflammation, autoimmunity, and cancer, which require repeated antibody administrations. The rapidity and reproducibility with which XenoMouse II yields a panel of fully human high affinity antibodies indicates the potential advance it offers over other technologies for human antibody production. For example, in contrast to phage display, which requires intensive efforts to enhance the affinity of many of its derived antibodies and yields single chain Fvs or Fabs, Xenomouse II antibodies are high affinity fully intact immunoglobulins which can be produced from hybridomas without further engineering.

The strategy described here for creation of an authentic human humoral immune system in mice can be applied towards humanization of other multi-gene loci, such as the T cell receptor or the major histocompatibility complex, that govern other compartments of the mouse immune system (Jakobovits, 1994). Such mice would be valuable for elucidating the structure-function relationships of the human loci and their involvement in the evolution of the immune system.

25

INCORPORATION BY REFERENCE

All references cited herein, including patents, patent applications, papers, text books, and the like, and the references cited therein, to the extent that they are not already, are hereby incorporated herein by reference in their entirety. In addition, the following references are also incorporated by

reference herein in their entirety, including the references cited in such references

Abertsen et al. "Construction and characterization of a yeast artificial chromosome library containing seven haploid human genome equivalents" *Proc. Natl. Acad. Sci.* **87**: 4255-4259 (1990)

5

Anand et al. "Construction of yeast artificial chromosome libraries with large inserts using fractionation by pulsed-field gel electrophoresis" *Nucl. Acids Res.* **17**: 3425-3433 (1989)

Berman et al. "Content and organization of the human Ig VH locus, definition of three new V_H families and linkage to the Ig C_H locus" *EMBO J.* **7**: 727-738 (1988)

Brezinschek et al. "Analysis of the heavy chain repertoire of human peripheral B-cells using single-cell polymerase chain reaction" *J. Immunol.* **155**: 190-202 (1995)

15 Brownstein et al. "Isolation of single-copy human genes from a library of yeast artificial chromosome clones" *Science* **244**: 1348-1351 (1989)

Bruggemann et al. *PNAS USA* **86**: 6709-6713 (1989)

20 Bruggemann et al. "Human antibody production in transgenic mice, expression from 100 kb of the human IgH locus" *Eur. J. Immunol.* **21**: 1323-1326 (1991)

Bruggeman, M. and Neuberger, M.S. in *Methods: A companion to Methods in Enzymology* **2**: 159-165 (Lerner et al. eds. Academic Press (1991))

25

Bruggemann, M. and Neuberger, M.S. "Strategies for expressing human antibody repertoires in transgenic mice" *Immunology Today* **17**: 391-397 (1996)

Chen et al. "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted

deletion of the J_{H} locus" *International Immunology* 5 647-656 (1993)

Choi et al. "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome" *Nature Genetics* 4 117-123 (1993)

5

Coligan et al., Unit 21, "Enzyme-linked immunosorbent assays," in *Current protocols in immunology* (1994)

Cook, G.P. and Tomlinson, I.M., "The human immunoglobulin V_{H} repertoire" *Immunology Today*

10 16.237-242 (1995)

Cox et al., "A directory of human germ-line V_{H} segments reveals a strong bias in their usage." *Eur. J. Immunol.* 24 827-836 (1994)

15 Dariavach et al., "The mouse IgH 5'-enhancer" *Eur. J. Immunol.* 21 1499-1504 (1991)

Den Dunnen et al., "Reconstruction of the 2.4 Mb human DMD-gene by homologous YAC recombination" *Human Molecular Genetics* 1 19-28 (1992)

20 Feeney, A J "Lack of N regions in fetal and neonatal mouse immunoglobulin V-D-J junctional sequences" *J. Exp. Med.* 172 137-1390 (1990)

Fishwild et al., "High-avidity human IgG κ monoclonal antibodies from a novel strain of minilocus transgenic mice." *Nature Biotech.* 14 845-851 (1996)

25

Flanagan, J G and Rabbitts, T.H., "Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ , ϵ , and α genes" *Nature* 300:709-713 (1982)

Galfré, G. and Milstein, C., "Preparation of monoclonal antibodies: strategies and procedures" *Methods Enzymol.* 73:3-4c (1981).

Gemmell et al., "Protocols for pulsed field gel electrophoresis: Separation and detection of large DNA molecules" *Advances in Genome Biology*, 1:217-251 (1991).

Gill et al., "Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity" *J. Biol. Chem.* 259:7755 (1984)

10

Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs" *Nature Genetics* 13:21 (1994)

15

Hermanson et al., "Rescue of end fragments of yeast artificial chromosomes by homologous recombination in yeast" *Nucleic Acids Res.* 19:4943-4948 (1991)

Huber et al., "The human immunoglobulin κ locus: Characterization of the partially duplicated L regions" *Eur. J. Immunol.* 23:2860-2967 (1993)

20

Jakobovits, A., "Humanizing the mouse genome" *Current Biology* 4:761-763 (1994)

Jakobovits, A., "Production of fully human antibodies by transgenic mice" *Current Opinion in Biotechnology* 6:561-566 (1995)

25

Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome" *Nature* 362:255-258 (1993)

Jakobovits, A. et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production" *Proc. Natl. Acad.*

Sci. USA 90 2551-2555 (1993)

Kawamoto et al., "Growth stimulation of A431 cells by epidermal growth factor. Identification of high affinity receptors for EGF by an anti-receptor monoclonal antibody" *Proc. Nat. Acad. Sci., USA* 80 1337-1341 (1983)

Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications." *Nature* 368 856-859 (1994)

10 Lusti-Marasimhan et al., "Mutation of Leu25 and Val27 introduces CC chemokine activity into interleukin-8" *J. Biol. Chem.* 270 2716-2721 (1995)

15 Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes" *Eur. J. Immunol.* 21 985-991 (1991).

Matsuda et al., "Structure and physical map of 64 variable segments in the 3' 0.8-megabase region of the human immunoglobulin heavy-chain locus." *Nature Genetics* 3 88-94 (1993).

20 Max E. *Molecular genetics of immunoglobulins. Fundamental Immunology*. 315-382 (Paul, WE, ed., New York: Raven Press (1993))

Mendez et al., "A set of YAC targeting vectors for the interconversion of centric and acentric arms." *Cold Spring Harbor Laboratory Press. Genome Mapping and Sequencing meeting*, 163 (1993)

25 Mendez et al., "Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic stem cells." *Genomics* 26 294-307 (1995)

Ray, S. and Diamond, B., "Generation of a fusion partner to sample the repertoire of Splenic B-cells

destined for apoptosis." *Proc. Natl. Acad. Sci. USA* 91:5548-5551 (1994).

Sato et al., "Biological effects *in vitro* of monoclonal antibodies to human epidermal growth factor receptors" *Mol. Biol. Med.* 1:511-520 (1983).

5

Schiestl, R.H. and Gietz, R.D., "High efficiency transformation of intact yeast cells using stranded nucleic acids as a carrier." *Curr. Genet.* 16:339-346 (1989).

10 Sherman et al., "Laboratory Course Manual for Methods in Yeast Genetics" (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1986))

Silverman et al., "Meiotic recombination between yeast artificial chromosomes yields a single clone containing the entire BCL2 protooncogene" *Proc. Natl. Acad. Sci. USA* 87:9913-9917 (1990).

15 Srivastava, A. and Schiessinger, D., "Vectors for inserting selectable markers in vector arms and human DNA inserts of yeast artificial chromosomes (YACs)" *Gene* 103:53-59 (1991).

Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins" *Nucleic Acids Research* 20:6287-6295 (1992).

20

Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM." *International Immunology* 6:579-591 (1994).

25 Tuuillion et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice gene-segment use in μ and γ transcripts" *Proc. Natl. Acad. Sci. USA* 90:3720-3724 (1993).

Tuuillion et al., "Analysis of direct and inverted DJ₁₁ rearrangements in a human Ig heavy chain transgenic minilocus" *J. Immunol.* 154:6453-6465 (1995).

Vaughan et al., "Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library" *Nature Biotech.* 14 309-314 (1996)

5 Wagner et al., "The diversity of antigen-specific monoclonal antibodies from transgenic mice bearing human immunoglobulin gene miniloci" *Eur. J. Immunol.* 24 2672-2681 (1994)

Weichhold et al., "The human immunoglobulin κ locus consists of two copies that are organized in opposite polarity" *Genomics* 16 503-511 (1993)

10 Yamada, M. et al., "Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes" *J. Exp. Med.* 173 395-407 (1991).

SCIENCE LISTING

GENERAL INFORMATION

1. APPLICANT: Abzenix, Inc.

1. TITLE OF THE INVENTION: TRANSGENIC MAMMALS HAVING HUMAN IgG4C1
INCLUDING PIVOTAL VH AND VK

NUMBER OF SEQUENCES 81

(iv) CORRESPONDENCE ADDRESS

(A) ADDRESSEE Fitch & Neave
(B) STREET 1251 Avenue of the Americas
(C) CITY New York
(D) STATE NY
(E) COUNTRY USA
(F) ZIP 10020

1. COMPUTER READABLE FORM

- A) MEDIUM TYPE Diskette
- B) COMPUTER IBM Compatible
- C) OPERATING SYSTEM DOS
- D) SOFTWARE FastSEQ Version 1.5

4.4 CURRENT APPLICATION DATA

(A) APPLICATION NUMBER:
(B) FILING DATE: 03-DEC-1997
(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA

(A) APPLICATION NUMBER: 08-759,620
(B) FILING DATE: 03-DEC-1996

(b)(6)(A) ATTORNEY/AGENT INFORMATION

(A) NAME: James, Huilev F
(B) REGISTRATION NUMBER: 27,794
(C) REFERENCE/DOCKET NUMBER: Cell 4 18

6.1 TELECOMMUNICATION INFORMATION

(A) TELEPHONE 212-596-9000
(B) TELEFAX 212-596-9090
(C) TELEX

(2) INFORMATION FOR SEQ ID NO:

6. SEQUENCE CHARACTERISTICS

- (A) LENGTH 21 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) MOLECULE TYPE: cDNA
- (ii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 1.

CAGGTGCAGC TGGAGCACTC GG

22

(2) INFORMATION FOR SEQ ID NO 2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 2.

GCTGAGGGAC TAGAGTCCTG AGGA

24

(2) INFORMATION FOR SEQ ID NO 3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 3

TTACTGTGCG AGACAA

15

(2) INFORMATION FOR SEQ ID NO 4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(i) HYPOTHETICAL NO
 (ii) ANTISENSE NO
 (iii) FRAGMENT TYPE
 (iv) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION SEQ ID NO 4

GGGAGCTTACG CG 12

(2) INFORMATION FOR SEQ ID NO 5

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 12 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL: NO
 (iv) ANTISENSE: NO
 (v) FRAGMENT TYPE
 (vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION SEQ ID NO 5

GAATCTCTGG CG 12

(2) INFORMATION FOR SEQ ID NO 6

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 11 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL: NO
 (iv) ANTISENSE: NO
 (v) FRAGMENT TYPE
 (vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION SEQ ID NO 6

TTACTGGGG AGAGAA 15

(2) INFORMATION FOR SEQ ID NO 7

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 16 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL: NO

- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 7.

CTTTGACTAC TGGGGC 16

(2) INFORMATION FOR SEQ ID NO 8:

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 8

TTACTGTACC ACAGA 15

(2) INFORMATION FOR SEQ ID NO 9:

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 11 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 9

ACTAACTTACCC 11

(2) INFORMATION FOR SEQ ID NO 10:

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO

(i) FRAGMENT TYPE
(ii) ORIGINAL SOURCE

(iii) SEQUENCE DESCRIPTION SEQ ID NO: 11

CTACTAATAC TACGGT 16

(iv) INFORMATION FOR SEQ ID NO: 11

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 15 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE

(vi) ORIGINAL SOURCE

(vii) SEQUENCE DESCRIPTION SEQ ID NO: 11

TTACTCTGCC AGAGA 15

(viii) INFORMATION FOR SEQ ID NO: 12

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 10 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE

(vi) ORIGINAL SOURCE

(vii) SEQUENCE DESCRIPTION SEQ ID NO: 12

TAGGAGTGT 10

(viii) INFORMATION FOR SEQ ID NO: 13

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 17 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE

(iv) ORIGINAL SOURCE

(a) SEQUENCE DESCRIPTION SEQ ID NO 13

CTAGTAAACAG CTCTAT 17

(2) REFORMATION FOR SEQ ID NO 14

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO 14

ACTACTACTA CTACGCT 17

(2) INFORMATION FOR SEQ ID NO 15

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO 15

TTACTGTGCG AGAC 14

(2) REFORMATION FOR SEQ ID NO 16

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(i) SEQUENCE DESCRIPTION: SEQ ID NO: 17

GCA GCA GCTG

(2) INFORMATION FOR SEQ ID NO: 17

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17

CTTTCACTAC TGGGCC

16

(2) INFORMATION FOR SEQ ID NO: 18

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18

TTACTGTGCG AGAGA

15

(2) INFORMATION FOR SEQ ID NO: 19

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19

GATATTTGA CTGGT

15

(2) INFORMATION FOR SEQ ID NO.20

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(vii) SEQUENCE DESCRIPTION: SEQ ID NO.20:

CTACTACTAC TACGGT

16

(2) INFORMATION FOR SEQ ID NO.21

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(vii) SEQUENCE DESCRIPTION: SEQ ID NO.21:

TTACTGTGCGAGAGA

15

(2) INFORMATION FOR SEQ ID NO.22

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 15 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(vii) SEQUENCE DESCRIPTION: SEQ ID NO.22:

TTTCACTACTGGGG

15

2 INFORMATION FOR SEQ ID N 23

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 23

TTACTGTGCG AGAGA

15

(2) INFORMATION FOR SEQ ID NO 24

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 13 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 24

TACTACTACT ACTAAGGT

18

(2) INFORMATION FOR SEQ ID NO 25

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 12 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 25

ATTACTGTGCGA

12

(2) INFORMATION FOR SEQ ID NO 26

(1) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(a) SEQUENCE DESCRIPTION: SEQ ID NO: 26

TATAGCACTG GCTGGT 16

(2) INFORMATION FOR SEQ ID NO 27:

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(a) SEQUENCE DESCRIPTION: SEQ ID NO: 27

CTTTGACTAC TGGGGC 16

(2) INFORMATION FOR SEQ ID NO 28

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 14 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(a) SEQUENCE DESCRIPTION: SEQ ID NO: 28

TATTACTCTG CGAC 14

(2) INFORMATION FOR SEQ ID NO 29

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 12 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i) MOLECULE TYPE: cDNA
 (ii) HYPOTHETICAL: NO
 (iii) ANTISENSE: NO
 (iv) FRAGMENT TYPE:
 (v) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO: 29

GAATCACTGGC GC 12

(2) INFORMATION FOR SEQ ID NO 30

(A) SEQUENCE CHARACTERISTICS
 (i) LENGTH: 12 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i) MOLECULE TYPE: cDNA
 (ii) HYPOTHETICAL: NO
 (iii) ANTISENSE: NO
 (iv) FRAGMENT TYPE:
 (v) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO: 30

TATTAATCTTC CG 12

(2) INFORMATION FOR SEQ ID NO 31

(A) SEQUENCE CHARACTERISTICS
 (i) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(i) MOLECULE TYPE: cDNA
 (ii) HYPOTHETICAL: NO
 (iii) ANTISENSE: NO
 (iv) FRAGMENT TYPE:
 (v) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO: 31

GGATATAGTA GTCW 14

(2) INFORMATION FOR SEQ ID NO 32

(A) SEQUENCE CHARACTERISTICS
 (i) LENGTH: 16 base pairs

(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE

(a) SEQUENCE DESCRIPTION: SEQ ID NO 32

CTTTGACTAC TGGGGC 16

(2) INFORMATION FOR SEQ ID NO 33:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE

(a) SEQUENCE DESCRIPTION: SEQ ID NO 33:

TTACTGTGG AGACAA 15

(2) INFORMATION FOR SEQ ID NO 34:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE:
(vi) ORIGINAL SOURCE

(a) SEQUENCE DESCRIPTION: SEQ ID NO 34

ATGCTTTGAT ATCTGGG 18

(2) INFORMATION FOR SEQ ID NO 35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 18 base pairs
(B) TYPE: nucleic acid

(i) STRANDEDNESS single
 (ii) TOPOLOGY linear

(iii) MOLECULE TYPE cDNA
 (iv) HYPOTHETICAL NO
 (v) ANTISENSE NO
 (vi) FRAGMENT TYPE
 (vii) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 35

TTAAACGAAAC ACTAACCCC 18

(2) INFORMATION FOR SEQ ID NO 36

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 16 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL NO
 (iv) ANTISENSE NO
 (v) FRAGMENT TYPE
 (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 36

GATCACTTGGCCAA 16

(2) INFORMATION FOR SEQ ID NO 37

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
 (iii) HYPOTHETICAL NO
 (iv) ANTISENSE NO
 (v) FRAGMENT TYPE
 (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 37

ACAGGGCTAAC AGTTTACCTC 20

(2) INFORMATION FOR SEQ ID NO 38

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 14 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single

(D) TOPOLOGY linear

- (ii) MOLECULE TYPE cDNA
- (iii) HYPOTHETICAL NO
- (iv) ANTISENSE NO
- (v) FRAGMENT TYPE
- (vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION SEQ ID NO 38

GGACGTTGGG CCAA

14

(2) INFORMATION FOR SEQ ID NO 39

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH 17 base pairs
- (B) TYPE nucleic acid
- (C) STRANDEDNESS single
- (D) TOPOLOGY linear

- (ii) MOLECULE TYPE cDNA
- (iii) HYPOTHETICAL NO
- (iv) ANTISENSE NO
- (v) FRAGMENT TYPE
- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 39

AAGTATAACA GTGCCCG

17

(2) INFORMATION FOR SEQ ID NO 40

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH 16 base pairs
- (B) TYPE nucleic acid
- (C) STRANDEDNESS single
- (D) TOPOLOGY linear

- (ii) MOLECULE TYPE cDNA
- (iii) HYPOTHETICAL NO
- (iv) ANTISENSE NO
- (v) FRAGMENT TYPE
- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 40

ATTCACTTT CCGCCCT

16

(2) INFORMATION FOR SEQ ID NO 41

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH 18 base pairs
- (B) TYPE nucleic acid
- (C) STRANDEDNESS single
- (D) TOPOLOGY linear

- (i) MOLECULE TYPE: cDNA
- (ii) HYPOTHETICAL: NO
- (iii) ANTISENSE: NO
- (iv) FRAGMENT TYPE:
- (v) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO 41

ACACATATGAT AATCTCCC 18

(2) INFORMATION FOR SEQ ID NO 42

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 17 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO 42

GCTCACITTTT GGCAGA 16

(2) INFORMATION FOR SEQ ID NO 43

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE:
- (vi) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO 43

AAACTATAAT AGTTACCG 18

(2) INFORMATION FOR SEQ ID NO 44

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

(ii) HYPOTHETICAL NO
(iii) ANTISENSE NO
(iv) FRAGMENT TYPE
(v) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 44

GATCACCTTC GGCCAA 16

(2) INFORMATION FOR SEQ ID NO:45

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO 45

CAGGCATAATA GTTACCC 17

(2) INFORMATION FOR SEQ ID NO:46

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO 46

ATTCACCTTC GGCCCT 16

(2) INFORMATION FOR SEQ ID NO:47

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 16 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(i) ANTISENSE NO
(ii) FRAGMENT TYPE
(iii) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 47

AATATTAGT-TACTG 16

(2) INFORMATION FOR SEQ ID NO 48

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 16 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE

(vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 48

GCTCACTTTCGGCGGA 16

(2) INFORMATION FOR SEQ ID NO 49

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE

(vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 49

CAGTATGGCA GCTCACTTC 19

(2) INFORMATION FOR SEQ ID NO 50

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 10 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(vi) FRAGMENT TYPE
 (vii) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50

CACTTTGGCCAG

(2) INFORMATION FOR SEQ ID NO:51

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:51

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg

1 5 10 15

Ser Thr Ser Thr

20

(2) INFORMATION FOR SEQ ID NO:52

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 80 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:52

Leu Ser Leu Thr Lys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr

1 5 10 15

Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Glu Leu Glu Trp Ile Gly

20 25 30

Glu Ile Asn His Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser

35 40 45

Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys

50 55 60

Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg

65 70 75 80

(I) INFORMATION FOR SEQ ID NO: 53

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 111 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 53

Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr
 1 5 10 15
 Trp Ser Trp Ile Arg Cln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
 20 25 30
 Gly Ile Asn Cln Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser
 35 40 45
 Arg Val Ile Ile Ser Ile Asp Thr Ser Lys Thr Cln Phe Ser Leu Lys
 50 55 60
 Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 65 70 75 80
 Glu Thr Pro His Ala Phe Asp Ile Trp Gly Cln Gly Thr Met Val Thr
 85 90 95
 Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
 100 105 110
 Cys Ser Arg Ser Thr Ser Thr
 115

(II) INFORMATION FOR SEQ ID NO: 54

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 120 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 54

Leu Ser Leu Thr Cys Ala Val Tyr Gly Gly Ser Phe Ser Gly Tyr Tyr
 1 5 10 15
 Trp Thr Trp Ile Arg Cln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
 20 25 30
 Glu Ile Ile His His Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser
 35 40 45

Arg Val Ser Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Thr
 50 55 60
 Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 65 70 75 80
 Gly Gly Ala Val Ala Ala Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
 85 90 95
 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
 100 105 110
 Pro Cys Ser Arg Ser Thr Ser Thr
 115 120

(2) INFORMATION FOR SEQ ID NO:55

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 84 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 55

Ser His His Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr
 1 5 10 15
 Ser Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu
 20 25 30
 Trp Met Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro
 35 40 45
 Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr
 50 55 60
 Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr
 65 70 75 80
 Tyr Cys Ala Arg

(2) INFORMATION FOR SEQ ID NO 56

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 121 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 56

Ser Leu Leu Ile Ser Ile Leu Asn Ser Glu Tyr Ser Phe Ile Ser Tyr
 1 5 10 15
 Ile Ile Gly Trp Val Arg Ile Met Pro Ile Ile Asp Leu Ile Trp Met
 20 25 30
 Gly Ile Ile Phe Pro Gly Asp Ser Asp Thr Asp Tyr Ser Pro Ser Phe
 35 40 45
 Glu Gly Glu Val Thr Ile Ser Asp Asp Lys Ser Ile Ser Thr Ala Tyr
 50 55 60
 Leu Glu Trp Ser Ser Leu Lys Ala Ser Asp Thr Asp Ala Met Tyr Tyr Gly
 65 70 75 80
 Ala Arg Glu Asp Glu Asp Ser Phe Asp Tyr Trp Gly Glu Gly Thr Leu
 85 90 95
 Val Thr Val Ser Ser Ala Ser Thr Ile Asp Gly Pro Ser Val Phe Pro Leu
 100 105 110
 Ala Pro Cys Ser Arg Ser Thr Ser Thr
 115 120

(2) INFORMATION FOR SEQ ID NO 57

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 83 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 57

Arg Ser Leu Arg Leu Ser Cys Ala Ser Asn Ser Glu Phe Thr Phe Ser Ser
 1 5 10 15
 Tyr Gly Met His Tyr Lys Arg Glu Ala Pro Glu Lys Gly Leu Glu Trp
 20 25 30
 Val Ala Val Ile Ser Tyr Asp Glu Ser Asp Lys Tyr Tyr Ala Asp Ser
 35 40 45
 Val Lys Glu Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr Leu
 50 55 60
 Tyr Leu Glu Met Asn Ser Leu Asp Ala Glu Asp Thr Ala Val Tyr Tyr
 65 70 75 80
 Cys Ala Arg

(2) INFORMATION FOR SEQ ID NO 58

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 122 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL NO
- (iv) ANTISENSE NO
- (v) FRAGMENT TYPE internal
- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION SEQ ID NO 58

Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
 1 5 10 15
 Tyr Gly Met His Trp Xaa Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
 20 25 30
 Val Ala Glu Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Val Asp Ser
 35 40 45
 Val Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
 50 55 60
 Tyr Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
 65 70 75 80
 Cys Ala Arg Asp Arg Leu Gly Ile Phe Asp Tyr Trp Gly Gln Gly Thr
 85 90 95
 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro
 100 105 110
 Leu Ala Pro Cys Ser Arg Ser Thr Ser Thr
 115 120

(2) INFORMATION FOR SEQ ID NO 59

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO 59

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 1 5 10 15
 Gln

(2) INFORMATION FOR SEQ ID NO 60

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 75 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO

(i) ANTISENSE NO:
 (ii) FRAGMENT TYPE: internal
 (vi) ORIGINAL SOURCE:

(d) SEQUENCE DESCRIPTION: SEQ ID NO: 60

Thr Ile Thr Cys Gin Ala Ser Gin Asp Ile Ser Asn Thr Leu Asn Trp
 1 5 10 15
 Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala
 20 25 30
 Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gin Pro Glu Asp Ile
 50 55 60
 Ala Thr Tyr Tyr Cys Gin Gin Asp Asp Asn Leu Pro
 65 70 75

(2) INFORMATION FOR SEQ ID NO 61:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO 61:

Thr Ile Thr Cys Gin Ala Ser Gin Asp Ile Ser Lys Phe Leu Ser Thr
 1 5 10 15
 Phe Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Gly Thr
 20 25 30
 Ser Tyr Leu Glu Thr Gly Val Pro Ser Ser Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gin Pro Glu Asp Val
 50 55 60
 Ala Thr Tyr Phe Cys Gin Gin Asp Asp Leu Pro Tyr Thr Phe Gly Pro
 65 70 75 80
 Gly Thr Lys Val Asp Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 85 90 95
 Ile Phe Pro Pro Ser Asp Glu Gin
 100

(2) INFORMATION FOR SEQ ID NO 62:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(d) SEQUENCE DESCRIPTION: SEQ ID NO 62.

Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp
 1 5 10 15
 Tyr Gln Gln Lys Ala Gly Lys Ala Pro Lys Val Leu Ile Tyr Ala Ala
 20 25 30
 Ser Asn Leu Glu Ala Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
 50 55 60
 Ala Thr Tyr Tyr Cys His Gln Asp Asn Leu Pro Leu Thr Phe Gly Gly
 65 70 75 80
 Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 85 90 95
 Ile Phe Pro Pro Ser Asp Glu Gln
 100

(2) INFORMATION FOR SEQ ID NO 63

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 74 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 63

Thr Cys Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln
 1 5 10 15
 Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser
 20 25 30
 Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
 35 40 45
 Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr
 50 55 60
 Tyr Tyr Cys Gln Gln Ser Tyr Ser Thr Pro
 65 70

(2) INFORMATION FOR SEQ ID NO 64

- (i) SEQUENCE CHARACTERISTICS
 - (A) LENGTH: 86 amino acids
 - (B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal
(vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 64

Thr Cys Arg Ala Ser Gin Ser Ile Ser Asn Tyr Ileu Asn Trp Tyr Gln
 1 5 10 15
 Gln Lys Pro Gly Lys Ala Pro Lys Phe Leu Ile Tyr Gly Ala Ser Ser
 20 25 30
 Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr
 35 40 45
 Asp Phe Thr Leu Thr Ile Ser Ser Ileu Gln Pro Glu Asp Phe Ala Thr
 50 55 60
 Tyr Tyr Cys Gln Gln Ser Tyr Ser Asn Pro Leu Thr Phe Gln Gln Gln
 65 70 75 80
 Thr Lys Val Glu Ile Lys
 85

(2) INFORMATION FOR SEQ ID NO 65

(i) SEQUENCE CHARACTERISTICS
(A) LENGTH: 81 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(iii) HYPOTHETICAL: NO
(iv) ANTISENSE: NO
(v) FRAGMENT TYPE: internal
(vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 65

Thr Ile Asn Cys Lys Ser Ser Gin Ser Val Leu Tyr Ser Ser Asn Asn
 1 5 10 15
 Lys Asn Tyr Leu Ala Trp Tyr Cys Gln Lys Pro Gly Gln Pro Pro Lys
 20 25 30
 Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg
 35 40 45
 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
 50 55 60
 Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Ser
 65 70 75 80
 Thr Pro

(2) INFORMATION FOR SEQ ID NO 66

(1) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 94 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO:66.

Thr Ile Asn Cys Lys Ser Ser Gin Ser Val Leu Tyr Ile Ser Asn Asn
 1 5 10 15
 Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys
 20 25 30
 Leu Leu Ile Tyr Trp Ala Ser Thr Arg Lys Ser Gly Val Pro Asp Arg
 35 40 45
 Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
 50 55 60
 Leu Gin Ala Glu Asp Val Ala Val Tyr Tyr Cys Gin Gin Tyr Tyr Asp
 65 70 75 80
 Thr Pro Phe Thr Phe Gly Pro Gly Tyr Lys Val Asp Ile Lys
 85 90

(2) INFORMATION FOR SEQ ID NO:67

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 20 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

(x) SEQUENCE DESCRIPTION: SEQ ID NO:67

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15
 Ser Thr Ser Thr
 20

(2) INFORMATION FOR SEQ ID NO:68

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 76 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) MOLECULE TYPE: peptide
- (ii) HYPOTHETICAL NO.
- (iii) ANTISENSE: no
- (iv) FRAGMENT TYPE: internal
- (v) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO: 68

Val Ser Gly Gly Ser Ile Ser Ser Gly Gly Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
 20 25 30
 Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 65 70 75

(2) INFORMATION FOR SEQ ID NO: 69

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 118 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL NO.
- (iv) ANTISENSE NO.
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(vi) SEQUENCE DESCRIPTION: SEQ ID NO: 69

Val Ser Gly Gly Ser Ile Asn Ser Gly Asp Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gln His Pro Gly Lys Gly Leu Asn Cys Ile Gly Tyr Ile Tyr Tyr
 20 25 30
 Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Val Asp Thr Ser Lys Asn Gln Phe Phe Leu Lys Leu Thr Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Ser Thr Val Val
 65 70 75 80
 Asn Pro Gly Trp Phe Asp Pro Trp Gly Gln Gly Tyr Leu Val Thr Val
 85 90 95
 Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys
 100 105 110
 Ser Arg Ser Thr Ser Thr
 115

(2) INFORMATION FOR SEQ ID NO: 70

- (i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 117 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) MOLECULE TYPE: peptide
- (ii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO:70

Val Ser Gly Gly Ser Ile Asn Ser Gly Asp Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr
 20 25 30
 Ser Gly Asn Thr Phe Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Leu Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Cys Tyr Cys Ala Arg Asn Ile Val Thr
 65 70 75 80
 Thr Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser
 85 90 95
 Ser Ala Ser Thr Lys Gln Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
 100 105 110
 Arg Ser Thr Ser Thr
 115

(2) CONFORMATION FOR SEQ ID NO:71

- (i) SEQUENCE CHARACTERISTICS
- (A) LENGTH: 116 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) MOLECULE TYPE: peptide
- (ii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:

(xi) SEQUENCE DESCRIPTION SEQ ID NO:71

Val Ser Gly Gly Ser Ile Ser Ser Gly Asp Tyr Tyr Trp Thr Trp Ile
 1 5 10 15
 Arg Gln His Pro Gly Lys Gly Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
 20 25 30
 Ser Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Ser Met
 35 40 45
 Ser Ile Asp Thr Ser Glu Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Lys Pro Val Thr

45 50 55 60
 Gly Glu Asp Thr Ile Glu Thr Ile Thr Leu Val Thr Val Ser Ser
 85 90 95
 Ala Ser Thr Leu Ile Pro Ser Val Phe Pro Leu Ala Ile Val Ser Asp
 100 105 110
 Ser Thr Ser Thr
 115

(2) INFORMATION FOR SEQ ID NO 72

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 76 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE

(vi) SEQUENCE DESCRIPTION: SEQ ID NO 72

Val Ser Gly Glu Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gln Pro Ile Gly Lys Ile Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
 20 25 30
 Ser Gly Ser Thr Asn Phe Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 65 70 75

(2) INFORMATION FOR SEQ ID NO 73

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 76 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE

(vi) SEQUENCE DESCRIPTION: SEQ ID NO 73

Val Ser Gly Glu Ser Val Ser Ser Gly Ser Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gln Pro Pro Gly Lys Glu Leu Glu Trp Ile Gly Tyr Ile Tyr Tyr
 20 25 30

Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Val Asp Thr Ser Ile Asn Gin Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 65 70 75

(2) INFORMATION FOR SEQ ID NO 74

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 117 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTISENSE: NO

- (v) FRAGMENT TYPE: internal

- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 74

Val Ser Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr Trp Ser Trp Ile
 1 5 10 15
 Arg Gin Pro Pro Gly Lys Ile Leu Glu Trp Ile Gly His Leu Tyr Tyr
 20 25 30
 Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile
 35 40 45
 Ser Leu Asp Thr Ser Lys Asn Gin Phe Ser Leu Lys Leu Ser Ser Val
 50 55 60
 Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala Arg Asp Phe Leu Thr
 65 70 75 80
 Gly Ser Phe Phe Asp Tyr Trp Gly Gin Gly Thr Leu Val Thr Val Ser
 85 90 95
 Ser Ala Ser Thr Cys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
 100 105 110
 Arg Ser Thr Ser Thr
 115

(2) INFORMATION FOR SEQ ID NO 75

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 17 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO 75

Arg Thr Ile Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
 1 5 10 15
 Glu

(2) INFORMATION FOR SEQ ID NO 76

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 75 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION: SEQ ID NO 76

Thr Ile Phe Cys Gin Ala Ser Gin Asp Ile Ser Asn Tyr Leu Asn Trp
 1 5 10 15
 Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala
 20 25 30
 Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gin Pro Glu Asp Ile
 50 55 60
 Ala Thr Tyr Ile Cys Gin Gin Asp Asn Leu Pro
 65 70 75

(2) INFORMATION FOR SEQ ID NO 77

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 104 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTISENSE: NO

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION: SEQ ID NO 77

Thr Ile Thr Cys Gin Ala Ser Gin Asp Ile Asn Asn Tyr Leu Asn Trp
 1 5 10 15
 Phe Gin Gin Lys Pro Gly Lys Ala Pro Lys Val Leu Ile His Asp Ala
 20 25 30
 Ser Asn Leu Glu Thr Gly Gly Pro Ser Arg Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Cys Leu Gin Pro Glu Asp Ile

50	55	60	
Ala Thr Tyr Tyr Cys Gln Gin Glu Ser Leu Pro Leu Thr Phe Gly			
65	70	75	80
Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe			
85	90	95	
Ile Phe Pro Pro Ser Asp Glu Gln			
100			

(2) INFORMATION FOR SEQ ID NO:78

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE peptide

- (iii) HYPOTHETICAL: NO
- (iv) ANTISENSE: NO
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78

Thr Ile Thr Cys Gin Ala Ser Gln Asp Ile Thr Ile Tyr Leu Asn Trp
 1 5 10 15
 Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Asn Asp Ala
 20 25 30
 Ser Ser Leu Glu Thr Gly Val Pro Leu Arg Phe Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Ile
 50 55 60
 Ala Thr Tyr Tyr Cys Gin Gin Asp His Leu Pro Leu Thr Phe Gly Gly
 65 70 75 80
 Gly Thr Ile Val Ala Ile Lys Arg Thr Val Ala Ala Pro Ser Val Phe
 85 90 95
 Ile Phe Pro Pro Ser Asp Glu Gln
 100

(2) INFORMATION FOR SEQ ID NO:79

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 194 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) HOMOLOGY: linear

(ii) MOLECULE TYPE peptide

- (iii) HYPOTHETICAL NO
- (iv) ANTISENSE NO
- (v) FRAGMENT TYPE internal
- (vi) ORIGINAL SOURCE

(x) SEQUENCE DESCRIPTION SEQ ID NO: 79

Thr Ile Thr Cys Asn Ala Ser Asn Asp Ile Ser Asn Tyr Ile
 1 5 10 15
 Tyr Asn Glu Lys Pro Cys Ile Ala Pro Ile Leu Leu Ile Tyr Asp Ala
 20 25 30
 Ser Asn Leu Glu Thr Ile Val Pro Ser Arg Ile Ser Gly Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Asn Asn Pro Ile Asp Val
 50 55 60
 Gly Thr Tyr Tyr Val Glu Glu Glu Ser Leu Pro Cys Gly Phe Gly Glu
 65 70 75 80
 Gly Thr Ivs Leu Glu Ile Ivs Arg Thr Val Ala Ala Pro Ser Val Phe
 85 90 95
 Ile Phe Pro Pro Ser Asp Glu Glu
 100

(2) INFORMATION FOR SEQ ID NO 80

(i) SEQUENCE CHARACTERISTICS

- (A) LENGTH: 104 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (i) MOLECULE TYPE: peptide
- (ii) HYPOTHETICAL: NO
- (iii) ANTISENSE: NO
- (iv) FRAGMENT TYPE: internal
- (v) ORIGINAL SOURCE:

(ii) SEQUENCE DESCRIPTION: SEQ ID NO 80

Thr Ile Thr Cys Glu Ala Ser Glu Asp Ile Ser Asn Tyr Ile Asn Trp
 1 5 10 15
 Tyr Cys Glu Lys Pro Cys Lys Ala Pro Ivs Leu Leu Ile Asn Asp Ala
 20 25 30
 Ser Asp Leu Glu Thr Gly Val Pro Ser Arg Ile Ser Gly Ser
 35 40 45
 Gly Thr Asp Phe Thr Phe Thr Ile Ser Asn Leu Glu Pro Glu Asp Ile
 50 55 60
 Ala Thr Tyr Tyr Cys Glu Glu Asp Ser Leu Pro Leu Thr Phe Gly Gly
 65 70 75 80
 Gly Thr Ivs Val Glu Ile Arg Arg Thr Val Ala Ala Pro Ser Val Phe
 85 90 95
 Ile Phe Pro Pro Ser Asp Glu Glu
 100

CLAIMSWHAT IS CLAIMED IS:

1. A transgenic non-human mammal having a genome, the genome comprising
5 modifications, the modifications comprising:

an inactivated endogenous immunoglobulin (Ig) locus, such that the mammal would
not display normal B-cell development;

10 an inserted human heavy chain Ig locus in substantially germline configuration, the
human heavy chain Ig locus comprising a human mu constant region and regulatory and
switch sequences thereto, a plurality of human J_H genes, a plurality of human D_H genes, and
a plurality of human V_H genes; and

an inserted human kappa light chain Ig locus in substantially germline configuration,
the human kappa light chain Ig locus comprising a human kappa constant region, a plurality
of J_K genes, and a plurality of V_K genes,

15 wherein the number of V_H and V_K genes inserted are selected to substantially restore normal
B-cell development in the mammal

2. The mammal of Claim 1, wherein the heavy chain Ig locus comprises a second
constant region selected from the group consisting of human gamma-1, human gamma-2, human
gamma-3, human gamma-4, alpha, epsilon, and delta.

20 3. The mammal of Claim 1, wherein the number of V_H genes is greater than about 20

4. The mammal of Claim 1, wherein the number of V_K genes is greater than about 15.

5. The mammal of Claim 1, wherein the number of D_H genes is greater than about 25,
the number of J_H genes is greater than about 4, the number of V_H genes is greater than about 20, the
number of J_K genes is greater than about 4, and the number of V_K genes is greater than about 15.

25 6. The mammal of Claim 1, wherein the number of D_H genes, the number of J_H genes,
the number of V_H genes, the number of J_K genes, and the number of V_K genes are selected such that
the Ig loci are capable of encoding greater than about 1×10^5 different functional antibody sequence
combinations

7. The mammal of Claim 1, wherein in a population of mammals B-cell function is

reconstituted on average to greater than about 50% as compared to wild type

8. In a transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous antibody molecules, the improvement comprising:

insertion into the genome of the mammal of sufficient human V_H , D_H , J_H , V_K , and J_K genes such that the mammal is capable of encoding greater than about 1×10^6 different functional human immunoglobulin sequence combinations, without accounting for junctional diversity or somatic mutation events.

10. 9. In a transgenic non-human mammal having a genome that comprises modifications, the modifications rendering the mammal capable of producing human immunoglobulin molecules but substantially incapable of producing functional endogenous antibody molecules, the modifications, with respect to the mammal's incapacity to produce functional endogenous antibody molecules would not allow the mammal to display normal B-cell development, the improvement comprising:

15. insertion into the genome of the mammal of sufficient human V_H , D_H , J_H , V_K , and J_K genes such that the mammal is capable of encoding greater than about 1×10^6 different functional human immunoglobulin sequence combinations and sufficient V_H and V_K genes to substantially restore normal B-cell development in the mammal.

10. 10. In the mammal of Claim 9, wherein in a population of mammals B-cell function is 20. reconstituted on average to greater than about 50% as compared to wild type

11. 11. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising:

an inactivated endogenous heavy chain immunoglobulin (Ig) locus;

an inactivated endogenous kappa light chain Ig locus,

25. an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of $\gamma H2$; and

an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of $\gamma K2$.

12. A transgenic non-human mammal having a genome, the genome comprising modifications, the modifications comprising

an inactivated endogenous heavy chain immunoglobulin (Ig) locus;

5 an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2, and

an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2.

13. A transgenic non-human mammal having a genome, the genome comprising 10 modifications, the modifications comprising

an inactivated endogenous heavy chain immunoglobulin (Ig) locus;

an inactivated endogenous kappa light chain Ig locus;

15 an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region; and

an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2.

14. A transgenic non-human mammal having a genome, the genome comprising 20 modifications, the modifications comprising

an inactivated endogenous heavy chain immunoglobulin (Ig) locus;

an inactivated endogenous kappa light chain Ig locus;

25 an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yH2 without the presence of a human gamma-2 constant region; and

an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of yK2.

15. A transgenic non-human mammal having a genome, the genome comprising

modifications, the modifications comprising

an inactivated endogenous heavy chain immunoglobulin (Ig) locus,

an inserted human heavy chain Ig locus, the human heavy chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of γ H2 without the presence of a human gamma-2 constant region, and

5 an inserted human kappa light chain Ig locus, the human kappa light chain Ig locus comprising a nucleotide sequence substantially corresponding to the nucleotide sequence of γ K2

16 A method for the production of human antibodies, comprising:

10 inoculating a mammal of any one of Claims 1-10 with an antigen,

collecting and immortalizing lymphocytic cells to obtain immortal cell lines secreting human antibodies that specifically bind to the antigen with an affinity of greater than 10^9 M⁻¹, and

15 isolating the antibodies from the immortal cell lines

17 The method of Claim 11, wherein the antigen is IL-8

18 The method of Claim 11, wherein the antigen is EGFR

19 The method of Claim 11, wherein the antigen is TNF- α

20 An antibody produced by the method of Claim 11

21 An anti-IL-8 antibody produced by the method of Claim 12

20 22 An anti-EGFR antibody produced by the method of Claim 13

23 An anti-TNF- α antibody produced by the method of Claim 14

24 In a method for the production of transgenic mice, the transgenic mice having a genome, the genome comprising modifications, the modifications comprising insertion of a plurality of human variable regions, the improvement comprising

25 insertion of the human variable regions from a yeast artificial chromosome

26 Transgenic mice and transgenic offspring therefrom produced through use of the improvement of Claim 19


26 In a transgenic mammal, the transgenic mammal comprising a genome, the genome comprising modifications, the modifications comprising an inserted human heavy chain


immunoglobulin transgene, the improvement comprising

the transgene comprising selected sets of human variable region genes that enable human-like junctional diversity and human-like complementarity determining region 3 (CDR3) lengths

5 27. In the improvement of Claim 26, wherein the human-like junctional diversity comprises average N-addition lengths of 7-7 bases.

28. In the improvement of Claim 26, wherein the human-like CDR3 lengths comprise between about 2 through about 25 residues with an average of about 14.



**FIGURE 2**




FIGURE 3




FIGURE 4




FIGURE 5

FIGURE 6

A1


Human Y₄

ASTKGRPSVTPLAPCSRSK

VH (D_H/J_H)	CDR1	CDR2	CDR3	CDR4	CDR5	CDR6	CDR7	CDR8	CDR9	CDR10	CDR11	CDR12	CDR13	CDR14	CDR15	CDR16	CDR17	CDR18	CDR19	CDR20	CDR21	CDR22	CDR23	CDR24	CDR25	CDR26	CDR27	CDR28	CDR29	CDR30	CDR31	CDR32	CDR33	CDR34	CDR35	CDR36	CDR37	CDR38	CDR39	CDR40	CDR41	CDR42	CDR43	CDR44	CDR45	CDR46	CDR47	CDR48	CDR49	CDR50	CDR51	CDR52	CDR53	CDR54	CDR55	CDR56	CDR57	CDR58	CDR59	CDR60	CDR61	CDR62	CDR63	CDR64	CDR65	CDR66	CDR67	CDR68	CDR69	CDR70	CDR71	CDR72	CDR73	CDR74	CDR75	CDR76	CDR77	CDR78	CDR79	CDR80	CDR81	CDR82	CDR83	CDR84	CDR85	CDR86	CDR87	CDR88	CDR89	CDR90	CDR91	CDR92	CDR93	CDR94	CDR95	CDR96	CDR97	CDR98	CDR99	CDR100	CDR101	CDR102	CDR103	CDR104	CDR105	CDR106	CDR107	CDR108	CDR109	CDR110	CDR111	CDR112	CDR113	CDR114	CDR115	CDR116	CDR117	CDR118	CDR119	CDR120	CDR121	CDR122	CDR123	CDR124	CDR125	CDR126	CDR127	CDR128	CDR129	CDR130	CDR131	CDR132	CDR133	CDR134	CDR135	CDR136	CDR137	CDR138	CDR139	CDR140	CDR141	CDR142	CDR143	CDR144	CDR145	CDR146	CDR147	CDR148	CDR149	CDR150	CDR151	CDR152	CDR153	CDR154	CDR155	CDR156	CDR157	CDR158	CDR159	CDR160	CDR161	CDR162	CDR163	CDR164	CDR165	CDR166	CDR167	CDR168	CDR169	CDR170	CDR171	CDR172	CDR173	CDR174	CDR175	CDR176	CDR177	CDR178	CDR179	CDR180	CDR181	CDR182	CDR183	CDR184	CDR185	CDR186	CDR187	CDR188	CDR189	CDR190	CDR191	CDR192	CDR193	CDR194	CDR195	CDR196	CDR197	CDR198	CDR199	CDR200	CDR201	CDR202	CDR203	CDR204	CDR205	CDR206	CDR207	CDR208	CDR209	CDR210	CDR211	CDR212	CDR213	CDR214	CDR215	CDR216	CDR217	CDR218	CDR219	CDR220	CDR221	CDR222	CDR223	CDR224	CDR225	CDR226	CDR227	CDR228	CDR229	CDR230	CDR231	CDR232	CDR233	CDR234	CDR235	CDR236	CDR237	CDR238	CDR239	CDR240	CDR241	CDR242	CDR243	CDR244	CDR245	CDR246	CDR247	CDR248	CDR249	CDR250	CDR251	CDR252	CDR253	CDR254	CDR255	CDR256	CDR257	CDR258	CDR259	CDR260	CDR261	CDR262	CDR263	CDR264	CDR265	CDR266	CDR267	CDR268	CDR269	CDR270	CDR271	CDR272	CDR273	CDR274	CDR275	CDR276	CDR277	CDR278	CDR279	CDR280	CDR281	CDR282	CDR283	CDR284	CDR285	CDR286	CDR287	CDR288	CDR289	CDR290	CDR291	CDR292	CDR293	CDR294	CDR295	CDR296	CDR297	CDR298	CDR299	CDR300	CDR301	CDR302	CDR303	CDR304	CDR305	CDR306	CDR307	CDR308	CDR309	CDR310	CDR311	CDR312	CDR313	CDR314	CDR315	CDR316	CDR317	CDR318	CDR319	CDR320	CDR321	CDR322	CDR323	CDR324	CDR325	CDR326	CDR327	CDR328	CDR329	CDR330	CDR331	CDR332	CDR333	CDR334	CDR335	CDR336	CDR337	CDR338	CDR339	CDR340	CDR341	CDR342	CDR343	CDR344	CDR345	CDR346	CDR347	CDR348	CDR349	CDR350	CDR351	CDR352	CDR353	CDR354	CDR355	CDR356	CDR357	CDR358	CDR359	CDR360	CDR361	CDR362	CDR363	CDR364	CDR365	CDR366	CDR367	CDR368	CDR369	CDR370	CDR371	CDR372	CDR373	CDR374	CDR375	CDR376	CDR377	CDR378	CDR379	CDR380	CDR381	CDR382	CDR383	CDR384	CDR385	CDR386	CDR387	CDR388	CDR389	CDR390	CDR391	CDR392	CDR393	CDR394	CDR395	CDR396	CDR397	CDR398	CDR399	CDR400	CDR401	CDR402	CDR403	CDR404	CDR405	CDR406	CDR407	CDR408	CDR409	CDR410	CDR411	CDR412	CDR413	CDR414	CDR415	CDR416	CDR417	CDR418	CDR419	CDR420	CDR421	CDR422	CDR423	CDR424	CDR425	CDR426	CDR427	CDR428	CDR429	CDR430	CDR431	CDR432	CDR433	CDR434	CDR435	CDR436	CDR437	CDR438	CDR439	CDR440	CDR441	CDR442	CDR443	CDR444	CDR445	CDR446	CDR447	CDR448	CDR449	CDR450	CDR451	CDR452	CDR453	CDR454	CDR455	CDR456	CDR457	CDR458	CDR459	CDR460	CDR461	CDR462	CDR463	CDR464	CDR465	CDR466	CDR467	CDR468	CDR469	CDR470	CDR471	CDR472	CDR473	CDR474	CDR475	CDR476	CDR477	CDR478	CDR479	CDR480	CDR481	CDR482	CDR483	CDR484	CDR485	CDR486	CDR487	CDR488	CDR489	CDR490	CDR491	CDR492	CDR493	CDR494	CDR495	CDR496	CDR497	CDR498	CDR499	CDR500	CDR501	CDR502	CDR503	CDR504	CDR505	CDR506	CDR507	CDR508	CDR509	CDR510	CDR511	CDR512	CDR513	CDR514	CDR515	CDR516	CDR517	CDR518	CDR519	CDR520	CDR521	CDR522	CDR523	CDR524	CDR525	CDR526	CDR527	CDR528	CDR529	CDR530	CDR531	CDR532	CDR533	CDR534	CDR535	CDR536	CDR537	CDR538	CDR539	CDR540	CDR541	CDR542	CDR543	CDR544	CDR545	CDR546	CDR547	CDR548	CDR549	CDR550	CDR551	CDR552	CDR553	CDR554	CDR555	CDR556	CDR557	CDR558	CDR559	CDR560	CDR561	CDR562	CDR563	CDR564	CDR565	CDR566	CDR567	CDR568	CDR569	CDR570	CDR571	CDR572	CDR573	CDR574	CDR575	CDR576	CDR577	CDR578	CDR579	CDR580	CDR581	CDR582	CDR583	CDR584	CDR585	CDR586	CDR587	CDR588	CDR589	CDR590	CDR591	CDR592	CDR593	CDR594	CDR595	CDR596	CDR597	CDR598	CDR599	CDR600	CDR601	CDR602	CDR603	CDR604	CDR605	CDR606	CDR607	CDR608	CDR609	CDR610	CDR611	CDR612	CDR613	CDR614	CDR615	CDR616	CDR617	CDR618	CDR619	CDR620	CDR621	CDR622	CDR623	CDR624	CDR625	CDR626	CDR627	CDR628	CDR629	CDR630	CDR631	CDR632	CDR633	CDR634	CDR635	CDR636	CDR637	CDR638	CDR639	CDR640	CDR641	CDR642	CDR643	CDR644	CDR645	CDR646	CDR647	CDR648	CDR649	CDR650	CDR651	CDR652	CDR653	CDR654	CDR655	CDR656	CDR657	CDR658	CDR659	CDR660	CDR661	CDR662	CDR663	CDR664	CDR665	CDR666	CDR667	CDR668	CDR669	CDR670	CDR671	CDR672	CDR673	CDR674	CDR675	CDR676	CDR677	CDR678	CDR679	CDR680	CDR681	CDR682	CDR683	CDR684	CDR685	CDR686	CDR687	CDR688	CDR689	CDR690	CDR691	CDR692	CDR693	CDR694	CDR695	CDR696	CDR697	CDR698	CDR699	CDR700	CDR701	CDR702	CDR703	CDR704	CDR705	CDR706	CDR707	CDR708	CDR709	CDR710	CDR711	CDR712	CDR713	CDR714	CDR715	CDR716	CDR717	CDR718	CDR719	CDR720	CDR721	CDR722	CDR723	CDR724	CDR725	CDR726	CDR727	CDR728	CDR729	CDR730	CDR731	CDR732	CDR733	CDR734	CDR735	CDR736	CDR737	CDR738	CDR739	CDR740	CDR741	CDR742	CDR743	CDR744	CDR745	CDR746	CDR747	CDR748	CDR749	CDR750	CDR751	CDR752	CDR753	CDR754	CDR755	CDR756	CDR757	CDR758	CDR759	CDR760	CDR761	CDR762	CDR763	CDR764	CDR765	CDR766	CDR767	CDR768	CDR769	CDR770	CDR771	CDR772	CDR773	CDR774	CDR775	CDR776	CDR777	CDR778	CDR779	CDR780	CDR781	CDR782	CDR783	CDR784	CDR785	CDR786	CDR787	CDR788	CDR789	CDR790	CDR791	CDR792	CDR793	CDR794	CDR795	CDR796	CDR797	CDR798	CDR799	CDR800	CDR801	CDR802	CDR803	CDR804	CDR805	CDR806	CDR807	CDR808	CDR809	CDR810	CDR811	CDR812	CDR813	CDR814	CDR815	CDR816	CDR817	CDR818	CDR819	CDR820	CDR821	CDR822	CDR823	CDR824	CDR825	CDR826	CDR827	CDR828	CDR829	CDR830	CDR831	CDR832	CDR833	CDR834	CDR835	CDR836	CDR837	CDR838	CDR839	CDR840	CDR841	CDR842	CDR843	CDR844	CDR845	CDR846	CDR847	CDR848	CDR849	CDR850	CDR851	CDR852	CDR853	CDR854	CDR855	CDR856	CDR857	CDR858	CDR859	CDR860	CDR861	CDR862	CDR863	CDR864	CDR865	CDR866	CDR867	CDR868	CDR869	CDR870	CDR871	CDR872	CDR873	CDR874	CDR875	CDR876	CDR877	CDR878	CDR879	CDR880	CDR881	CDR882	CDR883	CDR884	CDR885	CDR886	CDR887	CDR888	CDR889	CDR890	CDR891	CDR892	CDR893	CDR894	CDR895	CDR896	CDR897	CDR898	CDR899	CDR900	CDR901	CDR902	CDR903	CDR904	CDR905	CDR906	CDR907	CDR908	CDR909	CDR910	CDR911	CDR912	CDR913	CDR914	CDR915	CDR916	CDR917	CDR918	CDR919	CDR920	CDR921	CDR922	CDR923	CDR924	CDR925	CDR926	CDR927	CDR928	CDR929	CDR930	CDR931	CDR932	CDR933	CDR934	CDR935	CDR936	CDR937	CDR938	CDR939	CDR940	CDR941	CDR942	CDR943	CDR944	CDR945	CDR946	CDR947	CDR948	CDR949	CDR950	CDR951	CDR952	CDR953	CDR954	CDR955	CDR956	CDR957	CDR958	CDR959	CDR960	CDR961	CDR962	CDR963	CDR964	CDR965	CDR966	CDR967	CDR968	CDR969	CDR970	CDR971	CDR972	CDR973	CDR974	CDR975	CDR976	CDR977	CDR978	CDR979	CDR980	CDR981	CDR982	CDR983	CDR984	CDR985	CDR986	CDR987	CDR988	CDR989	CDR990	CDR991	CDR992	CDR993	CDR994	CDR995	CDR996	CDR997	CDR998	CDR999	CDR1000	CDR1001	CDR1002	CDR1003	CDR1004	CDR1005	CDR1006	CDR1007	CDR1008	CDR1009	CDR1010	CDR1011	CDR1012	CDR1013	CDR1014	CDR1015	CDR1016	CDR1017	CDR1018	CDR1019	CDR1020	CDR1021	CDR1022	CDR1023	CDR1024	CDR1025	CDR1026	CDR1027	CDR1028	CDR1029	CDR1030	CDR1031	CDR1032	CDR1033	CDR1034	CDR1035	CDR1036	CDR1037	CDR1038	CDR1039	CDR1040	CDR1041	CDR1042	CDR1043	CDR1044	CDR1045	CDR1046	CDR1047	CDR1048	CDR1049	CDR1050	CDR1051	CDR1052	CDR1053	CDR1054	CDR1055	CDR1056	CDR1057	CDR1058	CDR1059	CDR1060	CDR1061	CDR1062	CDR1063	CDR1064	CDR1065	CDR1066	CDR1067	CDR1068	CDR1069	CDR1070	CDR1071	CDR1072	CDR1073	CDR1074	CDR1075	CDR1076	CDR1077	CDR1078	CDR1079	CDR1080	CDR1081	CDR1082	CDR1083	CDR1084	CDR1085	CDR1086	CDR1087	CDR1088	CDR1089	CDR1090	CDR1091	CDR1092	CDR1093	CDR1094	CDR1095	CDR1096	CDR1097	CDR1098	CDR1099	CDR1100	CDR1101	CDR1102	CDR1103	CDR1104	CDR1105	CDR1106	CDR1107	CDR1108	

Human Ig Genes Reside on Large, Complex Loci

Human Heavy Chain Locus - Chromosome 14



Human Kappa Chain Locus - Chromosome 2




FIGURE 7

Reconstruction of Human Heavy Chain Locus on a Single YAC




FIGURE 8

Reconstruction of Human Kappa Chain Proximal Locus on a Single YAC





FIGURE 9

Phase II XenoMouse: Human Kappa Chain



- 800 kb YAC
- ~32 $V\kappa$ genes

FIGURE 10

1020 kb Heavy Chain YAC is Integrated Intact into the Mouse Genome

卷之三




FIGURE 11

800 kb Kappa Light Chain YAC is Integrated Intact into the Mouse Genome




FIGURE 12

B Cell Reconstitution In Xenomouse Blood





FIGURE 13

Production of Human Antibodies by XenoMouse II



* kept in pathogen-free conditions

FIGURE 14

Repertoire Analysis of Human Heavy Chain Transcripts Expressed in XenoMouse II Strains

Clone	V _H	D _H	N	J _H
A2.2.1	5 51 (DP 74)	TTACTGGCCGAGACAA	4 (TACGG)	AAUAA
B2.1.5	3 33 (DP 50)	TTACTGGCGAGATTA	7 (TCGGG;5A)	3TC
B4.2.4	3 15 (DP 38)	TTACTGACCCAGAA	1 (5)	GGUAC
B4.2.5	4 59 (DP 71)	TTACTGGGCGAGAA	10 (TAAG;2AG;GTT)	4 (A)AAAC(AAC;C)
D2.2.5	4 34 (DP 63)	TTACTGGGCGAGAG	2 (G)	GUAGGAG
D2.1.3	3 48 (DP 51)	TTACTGGCGAGACAA	4 (TCT)	TTTAA
D2.2.8	4 31 (DP 65)	TTACTGGCGAGAGA	2 (GA)	AA
A2.2.4	3 21 (DP 77)	TTACTGGCGAGAGA	2 (T)	RR
B4.2.11	4 44 35	TTTACGGGAGAA	1 (A)	TTAAGGAAAGGCGTCGG
C1.2.1	1 18 (DP 14)	TTTACTGGCGAG	0	XTCAGTAA / GATA
C3.1.2	4 39 (DP 79)	TTTACTGGCG	3 (GCT)	2 GCAAAAGAAAGG
D2.2.7	5 51 (DP 73)	TTACTGGCGAGACAA	4 (GTC)	KA AGUAGCA
				9 (GGGACACG)
				JH3 AGGCTTGGAAATGGGG
				JH4
				JH5
				JH6
				JH7
				JH8
				JH9
				JH10
				JH11
				JH12
				JH13
				JH14
				JH15
				JH16
				JH17
				JH18
				JH19
				JH20

FIGURE 15

Reertoire Analysis of Human Kappa Light Chain Transcripts Expressed in XenoMouse III Strains

Clone	V _κ	N	J _κ
F2 2 3	02(DPK0)	TTAACGAAACAGTACCCC	0
F4 1 8	15(DPK5)	ACAGGGCTAACAGTGTCCCC	0
F4 1 6	A2G(DPK4)	AAGTATAACAGTGTCCCC	0
F2 2 5	08	ACAGTATGATAATCTCCCC	0
F2 1 5	11	AAAGTATAATAGTTACCC	0
F2 1 4	A39	CAGGATAATAAGTGTACCC	0
F2 1 3	B3(DPK24)	AAATTTATAGTACCTCC	0
F4 1 3	A27M4-22	CAGTATGGTAGCTAACCTC	1(G)
			—CACCTTGGCCAG

FIGURE 16

Diverse Utilization of V_H and V_K Genes Present in XenoMouse II




FIGURE 17

High Antigen-Specific Human Antibody Response in XenoMouse

<u>Antigen</u>	<u>Titer</u>	<u>hIgM</u>	<u>hIgG</u>	<u>hIgK</u>
Human IL-8	7×10^5	1×10^6	4×10^6	
Human EGFR	4×10^5	7.5×10^5	3×10^6	
Human TNF α	4×10^5	4×10^5	3×10^5	

FIGURE 18

Composition of Anti-IL-8 Antibodies

Antibody	VH	D	JH	V _K	J _K
D1.1	4 - 34	21 - 10rc	JH3	018	JK3
K2.2	4 - 21	ir3rc	JH4	B3	JK3
K4.2	3 - 30	K1	JH4	018	JK4
K4.3	5 - 51	M5-4/M5-5-φ	JH4	012	JK4


FIGURE 19

IL-8 Antibodies: Heavy Chain Sequences

FIGURE 20

IL-8 Antibodies: Kappa Chain Sequences

Human CK



Anti-IL-8 Human Antibodies Block IL-8 Binding to Human Neutrophils




FIGURE 22
Anti-IL-8 Human Antibodies Block IL-8 Binding to Human Neutrophils

Inhibition of CD11b Expression on Human Neutrophils by Anti-IL-8 Antibodies




FIGURE 23

Inhibition of IL-8 Induced Ca^{+2} Influx by Anti-IL-8 Antibodies





FIGURE 24

Inhibition of IL8RB/293 Chemotaxis



Wang and Oppenheim, NCI

FIGURE 25

Rabbit Model of Human IL-8 Induced Skin Inflammation





FIGURE 26

Inhibition of IL-8-Induced Skin Inflammation in Rabbits by Anti-IL-8 Antibodies

Antibodies were administered i.v. single dose at 4mg/kg.



control human mAbs

FIGURE 27

Inhibition of Angiogenesis Rat Corneal Pocket Model

<u>Implant</u>	Angiogenesis (# Corneas)	
	<u>Positive</u>	<u>Negative</u>
IL-8 alone	15	1
IL-8 + Control MAb	4	1
IL-8 + D1.1	0	6
IL-8 + K2.2	1	5
IL-8 + K4.3	2	4

FIGURE 28

EGFR Antibody Gene Composition

Antibody	VH	D	JH	V κ	J κ
E1.1	4 - 31	2	JH5	018	J κ 4
E2.4	4 - 31	A1/A4	JH3	018	J κ 4
E2.5	4 - 31	XPI/21-10	JH4	018	J κ 4
E2.11	4 - 61	XPI/21-10	JH4	018	J κ 2

FIGURE 29

EGFR Antibodies: Heavy Chain Sequences

FIGURE 30

WO 98/24893
PCT/US97/23094

Anti-EGFR Human Antibodies Block EGF Binding to A431 Cells




FIGURE 31

Anti-Body Concentration (nM)

Inhibition of EGF Binding to SW948 Cells by Anti-EGFR Human Antibodies




FIGURE 32

Anti-EGFR Human Antibodies Inhibit SW948 Cell Growth




FIGURE 33

Inhibition of TNF α Binding to U937 Cells by Anti-TNF α Human Monoclonal Antibodies




FIGURE 34

anti-EGFR ANTIBODIES

Kappa Light Chain Y_k(J_k) Sequences

F1,1
TITQAVSQDQIILWYQQKRPQKAPKVL, IHDASHHEWVQPSRFSGSGGTIDFTFTIISGLQPEIDATYYCQQQFSLPLPQIGCTVYHFRV
AAPAVF1FPPPSDEQ;

F2,4
TITQAVSQDQIILWYQQKRPQKAPKVL, IHDASHHEWVPLPFSGSGGTIDFTFTIISGLQPEIDATYYCQQQFSLPLPQIGCTVYHFRV
AAPAVF1FPPPSDEQ;

F2,5
TITQAVSQDQIILWYQQKRPQKAPKLL, IYDASHHEETGVPSRISGSQSTIDFTFTIISSLQPEIDATYYVQQFSLPLPQIGCTVYHFRV
AAPAVF1FPPPSDEQ;

F2,11
TITQAVSQDQIILWYQQKRPKLLINEAS, DLEFTGVPSRISGSQSTIDFTFTIISLQPEIDATYYCQQQFSLPLPQIGCTVYHFRV
AAPAVF1FPPPSDEQ;

FIGURE 35



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A01K 67/027, C07K 16/00, 16/24, 16/28 // C12N 15/85, 15/90	A3	(11) International Publication Number: WO 98/24893
(21) International Application Number:	PCT/US97/23091	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, U, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date:	3 December 1997 (03.12.97)		
(30) Priority Data:	08/759,620 3 December 1996 (03.12.96) US		
(71) Applicant:	ABGENIX, INC. [US/US]; 7601 Dumbarton Circle, Fremont, CA 94555 (US)		
(72) Inventors:	JAKOBOVITS, Aya; 2021 Monterey Avenue, Menlo Park, CA 94025 (US). KUCHERLAPATI, Raju; 8 Gracie Lane, Darien, CT 06820 (US). KLAPHOLZ, Sue; 76 Peter Coutts Circle, Stanford, CA 94305 (US). MENDEZ, Michael; P.O. Box 787, El Granada, CA 94018 (US). GREEN, Larry; 70 Crestline Drive #2, San Francisco, CA 94131 (US).		
(74) Agents:	HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).		
(88) Date of publication of the international search report:	20 August 1998 (20.08.98)		

(54) Title: TRANSGENIC MAMMALS HAVING HUMAN Ig LOCI INCLUDING PLURAL V_H AND V_K REGIONS AND ANTIBODIES PRODUCED THEREFROM

(57) Abstract

The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (V_H and V_K) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.

Published

With international search report

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mah	TT	Trinidad and Tobago
BJ	Benin	IE	Iceland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Ireland	MW	Morawa	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroun			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russia Federation		
DE	Germany	LV	Liechtenstein	SD	Sudan		
DK	Dominican	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Lithuania	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US97/23091

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A01K 6/02 C07K 16/30 C07K 16/24 C07K 16/28 A01C 21/05
C12N 15/90

According to International Patent Classification (IPC), prior both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A01K C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	A. JAKOBOVITS ET AL., : "Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 764, 1995, NEW YORK, NY, US, pages 525-535, XP002067728 see the whole document but specially pages 533-534 ---	1-16

 Further documents are listed in the continuation of box C Patent family members are listed in annex

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier document but published on or after the international filing date

"C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"D" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

12 June 1998

25/06/1998

Name and mailing address of the ISA

European Patent Office, P.O. 5615 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: +31-701 340-2040, Fax: +31-651 400-01
Fax: +31-701 340-3015

Authorized officer

Matedo Roseij, A.M.

INTERNATIONAL SEARCH REPORT

C. Continuation DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Continuation document with indication where appropriate of the relevant disclosure	Relevant claims
A	WO 94 15566 A (SENPHEM INT) 10 November 1994 cited in the application see page 1, line 19-30 see page 6, line 24 - page 7, line 23 see page 11, line 6 - page 12, line 12 see page 23, line 25 - page 24, line 7 see page 48, line 35 - page 49, line 22 examples 1-5 see page 185, line 26 - page 190, line 31 see page 198, line 18-30 see page 202, line 16-36 ---	1-5, 6-10, 15, 14
A	WO 96 34096 A (CELL GENESYS INC) 31 October 1996 cited in the application see page 2, line 20-34 see page 13, paragraph 31-33 see page 15, line 14-21; examples 2,3 ---	1, 16, 17, 19-21, 23, 24
A	WO 91 00911 A (GENETICS INST) 24 January 1991 see the whole document ---	1, 11-16
A	L.D. TAYLOR ET AL.,: "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins" NUCLEIC ACIDS RESEARCH, vol. 20, no. 23, 1992, OXFORD, GB, pages 6287-6295, XP002041128 cited in the application see the whole document ---	1-16, 26-28
A	M. BRUGGEMAN AND N.S. NEUBERGER: "Strategies for expressing human antibody repertoires in transgenic mice" IMMUNOLOGY TODAY, vol. 17, no. 8, 1 August 1996, OXFORD, GB, pages 391-397, XP002067729 cited in the application see the whole document ---	1-28
P,X	M.J. MENDEZ: "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" NATURE GENETICS, vol. 15, no. 2 1 February 1997, NEW YORK, NY, US, pages 146-156, XP002067603 see the whole document ---	1-15
		-/-

INTERNATIONAL SEARCH REPORT

PCT/ISA/210 continuation of second sheet, July 1998

PCT/US97/10091

3. Continuation DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Character of document with indication where appropriate of the relevant passages	Relevant claim(s)
P,X	A. JAKOBOWITS ET AL., : "Human immunity in mice engineered with megabase human heavy and kappa light chain YACs" THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1, part 2, 1 January 1997, SAINT LOUIS, MO, US, page 3113 XP002067604 see abstract ----	1-15
P,X	J.R.F. CORVALAN ET AL., : "Generation of fully human high affinity monoclonal antibodies to EGF receptor in mice" THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1, part 2, 1 January 1997, SAINT LOUIS, MO, US, page 3214 XP002067605 see abstract ----	1,16,18, 20,22,24
P,X	X.D. YANG ET AL.,: "Human monoclonal antibodies to human TNF-alpha generated from mice carrying human Ig loci" THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1, part 2, 1 January 1997, SAINT LOUIS, MO, US, page 315 XP002067606 see abstract -----	1,16,19, 20,23,24

INTERNATIONAL SEARCH REPORT

Information on patient family members

Case Number	Defendant	Date of Birth	Arrest Date	Arrest Location	Arrest Status
NO 9405665	A	10-11-1994		2466895	A
				0823941	A
					15-02-1998